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1. Introduction  
It has been more than 100 years since the potential use of oncolytic viruses in cancer treatment was proposed, 
1 and we are still at the beginning to make use of this clever twist in nature that gives us the opportunity to 
use a pathogen to treat one of the most deadly diseases in the world. The huge time span between the initial 
hypothesis and finally the first approved viral cancer therapy reflects not only the challenges oncolytic viruses 
had to face, but also the promising prospects they offer that kept scientists motivated to continue their 
research. 
In viro-immunotherapy, the strategy is to optimise the combined effects of the virus’s inherent oncolytic 
properties and its ability to trigger an immune response at the tumor site, supporting the destruction of 
malignant cells and is at the same time a great approach to break the immune tolerance towards the tumor2. 
The challenge is to find a balance between the direct oncolytic effect of the virus and the induction of a 
strong immune response without clearing the virus before it can reach its maximum effect 3.  
In this study, the new pseudotyped oncolytic virus (rVSV-NDV) based on a vesicular stomatitis virus (VSV) 
backbone, with the attachment proteins of Newcastle disease virus (NDV) in place of the endogenous 
glycoprotein, is tested for its safety and efficacy in vivo. Findings, achieved in this study are partly already 
published in Journal of Virology 4 in December 2018. Parameters of interest were toxicity in virus-treated 
rodents with special attention to neuropathogenicity, as this is a major problem in VSV-treated rodents and 
non-human primates5, as well as pathogenicity in avian species, treatment-efficacy of the hybrid-virus in vivo 
and information about viral kinetics. 
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2. Literature Review 
2.1. Hepatocellular Carcinoma 
Liver cancer was the sixth common cancer worldwide in 2012 with rising incidence. It is listed as second 
common cancer-related cause of death 5. The high mortality rate in hepatocellular carcinoma (HCC) is due 
to the facts that HCC is often diagnosed in late stages and additionally is relatively unresponsive to 
chemotherapy. Today the most effective and curative treatment for HCC is surgical resection or liver 
transplantation at early stages of the disease 7. A major challenge in HCC therapy is that not even 40% of the 
patients are diagnosed at early stages, and later on, when the disease is more progressed, patients are often 
only eligible for palliative treatments 8. Even successfully treated patients face 70% recurrence rates and only 
a 30-50% chance of a five-year survival 7. 
The main catalysts for the development of HCC are, by a clear margin (60-70% of the reported HCC cases), 
Hepatitis C (HCV) and B virus (HCB) infections9. Further causalities that drive hepatic malignancy are 
alcoholic-liver disease, as well as non-alcoholic fatty liver disease and other autoimmune or hereditary liver 
disease such as hemochromatosis and Wilson’s disease10. The leading viral factor driving liver cancer depends 
on the prevalence of HCV and HBV in different regions. In northern Europe, the United States and Japan, 
HCV is predominant, and in Africa and Asia, HBV is the main cause6. Although these two viruses both cause 
HCC, their pathogenicity differs clearly. HCV is known to cause liver malignancy by indirect pathways. 
Inflammation of the liver leads to cell death, proliferation and therefore induces a high turnover of newly 
produced cells. In addition, cirrhosis occurs regularly in inflamed livers and complicates the treatment because 
of the reduced accessibility of infected cells. These circumstances promote an accumulation of mutations and 
can eventually lead to HCC. In fact, HCC caused by HCV infection is almost exclusively seen in patients with 
cirrhosis. HBV infection induces HCC additionally via a direct pathway. The direct mechanism includes 
genomic integration and interference with growth signalling of the cell 10.  
In 2012, 745.000 patients died from HCC. As the incidence of HCC is rising, even higher numbers can be 
expected in the future if no new treatment opportunities are developed.  
Although in humans HCC ranks high under newly diagnosed cancers with even rising incidence, in dogs and 
cats reported cases of HCC are less common. Nevertheless, 0.6-1.3% of canine neoplasms are primary hepatic 
tumors11. HCC is the most common primary liver cancer in dogs and the second most common primary liver 
cancer in cats. The cause of the disease in animals is unknown, although a correlation between old age and 
HCC incidence can be observed. The best treatment opportunity provides liver resection in early stages11. To 
prevent often old-aged patients from invasive surgery the establishment of an alternative and mild treatment 
protocol would be beneficial for the patient’s life quality. 
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2.2. Oncolytic Viruses 
Oncolytic viruses (OVs) are viruses that can specifically replicate in and lyse cancer cells, taking advantage of 
their often impaired interferon response. These viruses could become the new weapon in the fight against 
HCC. Very different from chemotherapeutic approaches that kill unspecific cells with a high turnover rate 
and are a threat to both, cancer and the patient, OVs offer a different angle of cancer treatment, as they can 
mediate both direct cytopathic effects in cancer cells, as well as a break in immune tolerance towards 
malignant cells and induction of adaptive immune responses directed at tumor antigens. They therefore 
exploit the body’s own resources to fight the disease using the new immunogenic trigger that the viral 
infection poses, combined with the direct oncolytic activities of the virus to lead to an immune response, not 
only directed against the virus but against tumor antigens as well. Since reverse genetics methods became 
standardized laboratory practice, it is possible to equip the virus with foreign genes, allowing the introduction 
of tumor antigens or proteins with specific antitumor functions into the targeted cells. This not only allows 
the use of viruses as vaccines, which provides the opportunity to vaccinate patients with a predisposition for 
special cancer types against typical epitopes and protect them from tumor challenge, but it also offers the 
possibility to cause infiltration of established tumors with immunologic components to attack the tumor cell. 
A prolonged survival of OV treated patients could also give hope for patients on the waiting list for liver 
transplantation. In recent years the number of patients dying while waiting for liver transplantation increased 
and only 69% survive their first year on the waiting list 12. 
It becomes apparent that OVs represent a promising anti-cancer agent combining several advantages. The 
question arises: what does a virus need in order to be an oncolytic virus? Two important aspects, which 
determine the oncolytic activity of a virus, are the tropism and interferon (IFN) sensitivity. These 
characteristics provide the specificity of the virus for malignant cells. The first thing to consider is whether 
the virus is able to target tumor cells and which other cells the virus might infect. The tropism describes an 
interplay between the ability of a virus to enter a cell (receptor dependent tropism) and the cell being a suitable 
host for viral replication and progeny production (receptor independent tropism)13. As viruses often target 
receptors present on many cell types, it is important for a cell that is not the natural target of the viral infection 
to be able to mount an anti-viral defense to protect itself from virus-mediated cytotoxicity. The natural cellular 
response to viral infection is to produce and release IFN to hinder viral replication in the affected cell and 
increase major histocompatibility complex I (MHC I) molecules on neighbouring cells to stop viral spreading 
and rapidly eradicate the virus from the system14. Malignant cells are often impaired in their IFN responses15 
to avoid detection by immune cells and thus allow IFN sensitive viruses to replicate effectively whereas non-
malignant cells clear the infection. 
Before a virus can be considered as a candidate for cancer therapy, there are certain aspects of its natural 
replication cycle to consider. Some of the features provided by OVs offer great advantages over conventional 
drugs. An example would be the increasing viral titer due to viral replication at the treatment site, compared 
to traditional therapeutic agents, in which the concentrations usually decline after application. Nevertheless, 
some of the viral properties also need to be carefully considered, as they can provide an unforeseeable risk in 
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a host, e.g. tropism to not only cancer cells, but neurons as well (VSV) or genomic integration and latent 
infection (herpes simplex virus, adeno-associated viruses). The replication process will be explained in closer 
detail later on for the parental viruses of rVSV-NDV. For now, the focus lies on the benefits and risks 
associated with different OVs at specific steps of infection. 
Viral entry and tropism are crucial for a successful infection. The attachment protein of a virus determines 
which cells can be infected and is the natural attribute that determines the host-specificity of a virus. Many 
of the OVs in clinical trials are animal viruses that had only restricted contact to humans, and thus, most 
patients do not face pre-existing immunity, allowing the virus to be more effective. To be considered 
oncolytic, the virus must of course enter and replicate in tumor cells, but it is also important to consider 
which other cells the virus is able to infect. A significant dose-limiting side effect of VSV is that it can result 
in neurotoxicity, because VSV is able to enter olfactory neurons and travel retrograde into the brain 16. On 
the other hand VSVs broad tropism allows entry in nearly all known types of human tissue17, and therefore, 
a broad variety of tumor cells is susceptible for infection. In general, viral attachment proteins are strongly 
immunogenic, and in many cases, vaccination against attachment proteins is enough to create a resilient 
immune response18. This poses a threat to the efficacy of oncolytic-viral treatment, as fast clearance of the 
virus is one of the main problems OV’s have to overcome. 
Once inside the cell, the virus uses the cell’s replication machinery or a combination of this with its own 
enzymes to create its individual components and copies of genetic material. Some viruses replicate in the 
cytoplasm and some in the nucleus of the host cell. Cytoplasmic replication offers some advantages over 
replication in the nucleus in the sense that some viruses are capable of genomic integration. As an additional 
feature, viruses replicating in the cytoplasm suppress host translation by interference with nuclear pores 
leading to cell death. 
Tumor cells that are successfully infected with an oncolytic virus tend to lead to immunogenic apoptosis. In 
contrast to cells undergoing a silent apoptosis, these can attract the attention of the immune system19 and 
lead to immunologic responses against the viral antigens as well as newly derived tumor cell antigens.  
2.3. Oncolytic Viruses in Clinical Trials 
Many viruses possess oncolytic potential, among them DNA viruses such as herpes simplex virus, vaccinia 
virus and adenovirus as well as RNA viruses like vesicular stomatitis virus (VSV) and Newcastle disease virus 
(NDV), which will be the centre of this study. Of these oncolytic viruses, each has its own set of benefits that 
contributes in a unique way to tumor destruction but all of them have similar obstacles to overcome. 
The adenovirus H101 is an approved oncolytic agent in china. It is deprived of the E1B gene, which 
inactivates the transcription factor p53 that stops cell proliferation when accumulated in a cell. A virus with 
this modification would be unable to replicate in a cell with normal p53 function, but not in a cancer cell 
lacking p53, which is a commonly seen genetic aberration in human cancer20. This leads to an undamped viral 
replication and finally cell burst from virus overload. Phase III trials in treatment of head and neck cancer 
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lead to 79% response rate for patients treated with H101 plus chemotherapy in comparison to a 40% response 
rate in chemotherapy only treated patients 21.  On the downside, this virus has a deletion in the E3 gene, 
which influences immune modulation e.g. by preventing the expression of MHC molecules or leading the 
transport of apoptosis receptors into lysosomes. As a result, H101 is eradicated from the patients system 
rather early and cannot be given intravenously, but only intratumorally. Also, the capacity as a vector for gene 
therapy is limited and makes the use of other viruses with the possibility to act as a platform for transfection 
superior. 
Another OV is the vaccinia virus. Jennerex Inc. has marketed the Wyeth strain of vaccinia virus as the basis 
of oncolytic JX-594. This vector has already been applied in Phase II trials. It is attenuated through a disrupted 
thymidine kinase gene and carries insertions to express human granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and β-galactosidase transgenes for an anti-tumor immune stimulation22. It is stable in 
delivery and shows enhanced potency combined with an efficient immune response compared to wild type 
vaccinia. More over the genome offers a large capacity for transgene encoding23. The tumor response to 
treatment with this oncolytic agent is highly dose dependant and is only available for systemic delivery in 
doses up from 109PFU. A disadvantage here is that 50 % of the patients have a baseline neutralizing antibody 
titer from vaccination against smallpox. 
Imlygic® (talimogene laherparepvec, T-VEC) is the first “US Food and Drug Administration” approved 
oncolytic virus. This genetically modified herpes simplex virus type 1 is approved for therapy against 
melanoma and acts as antitumor vaccine agent in injectable, non-resectable tumors. T-VEC is genetically 
engineered to enhance safety by deletion of infected cell protein (ICP) 34.5 and ICP 47 (neuro virulence 
factors) to undermine the viruses immune evasion mechanisms and  additionally contains a cassette encoding 
granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate antigen presenting cells 24.  These 
modifications not only allow healthy cells and neurons to clear the virus and prevent latent infections, but 
also alter immune presence in tumor tissue, which supports the virus in tumor destruction and offers antigenic 
material from tumor tissue to be used as a matrix. 16,3% of patients developed a durable response after being 
treated with T-VEC in comparison to 2.1% of GM-CSF treated patients with durable response 25. 
The focus of the work presented here is on a hybrid virus, constructed by merging components of two 
parental viruses, both of which have been shown to be oncolytic and have been applied in Phase I-III clinical 
trials.  
Different strains of NDV have been used as treatment for neoplastic diseases in 33 patients with advanced 
cancer, non-responsive to standard treatment. Attenuated NDV-MTH-68/N administered via inhalation 
showed objective favorable responses (regression and stabilization) in 55% and a one-year survival in 66% 
of treated patients in comparison to 8% objective favorable response in the placebo-group and 6.5% one-
year survival26. Also PV701 was extensively used in a Phase I and II clinical trial evaluating the maximum 
tolerated dose of this replication-competent OV for intravenous administration as a bolus (2.4x1010PFU for 
the first dose and 1.2x1011PFU for subsequent doses). Also, a slow-infusion administration system over one 
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to three hours was established, which led to increased patient tolerability and higher tolerated dose escalation 
for the first administration. 27 
Although many attempts exist to alter VSV’s characteristics as an oncolytic agent, from VSV-mp53 expressing 
murine p53 over VSV-TK that expresses tyrosine-kinase (TK) which can improve oncolysis in combination 
with the prodrug Ganciclovir, neurotoxicity remains a major challenge to the clinical translation of VSV.  
A promising approach to exploit the diverse advantages of the rhabdovirus VSV is under constant 
development and evaluation by the group of von Laer. They attempt to circumvent neurotoxicity, the major 
concern about this otherwise powerful oncolytic agent, by using a pseudotyped recombinant VSV with the 
Glycoprotein of the lymphocytic choriomeningitis virus (LCMV-GP). This recombinant (VSV-GP) has been 
tested in several in vitro and in vivo studies concerning neurotoxicity, systemic safety, off-target toxicity28, 
oncolytic activity in several cancer types (glioma28, ovarian cancer29,  malignant melanoma30 and prostate 
cancer31, it’s abilities to circumvent humoral immunity32  as well as it’s modulation abilities in tumor 
microenvironment33. Those studies have proven VSV-GP to be a potent candidate to boost oncolytic viruses 
into clinical translation and to elevate awareness of this treatment opportunity.  
VSV-GP turned out to be a safe oncolytic agent in terms of neurotoxicity. As the glycoprotein inherent to 
wildtype VSV is exchanged as mentioned above neurotropism is no longer mediated. Systemic application of 
the viral vector (109 PFU in immunodeficient CD-1 mice) led to a minor loss in body weight that the mice 
regained in only a few days after administration28. Off-target toxicity has examined by measurement of serum 
ALT, -creatinine and measurement of viral RNA by RT-PCR in blood, brain, heart, kidney, liver, lung and 
spleen. For the VSV-GP vector no off-target toxicity has been observed28. The oncolytic effect of the new 
vector was altogether promising but varied dependent on the tissue type. An additional feature that this 
recombinant virus provides is the ability to successfully circumvent humoral immunity what allows for a 
repetitive administration scheme32. Specifications will be given in the Discussion. 
Summarizing this overview, it can be concluded that there are different approaches to make use of oncolytic 
viruses as anti-cancer agents. So far all concerns about the tested viruses come down to a narrow set of 
obtacles. Namely, limited effectivity of the virus either due to pre-existing immunity, reduced susceptibility 
of the tumor cells to viral infection or a fast clearance of the oncolytic agent by the patient’s immune response 
and safety concerns due to toxic side effects or a reduced sensitivity of the virus to Interferon and therefore 
the host’s ability to restrict the infection. 
2.4. Immune Reactions to Viral Infections and Immune Evasion in Cancer 
A critical point in OV therapy is the clearance of the viral vector by the immune system. It is both, desired 
immediately in not-targeted cells and in the targeted tumor cells, but only at a specific point in time. The 
optimal point in time for immune interference of virus infected tumor cells would be when the virus has 
gained access to a majority of tumor cells. At this point the immune response could effectively support the 
virus in killing tumor cells and clear the virus from the system. Thus, a fast viral replication cycle, rapid viral 
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spread inside the tumor tissue and a delayed but strong immune response against viral and tumoral antigens 
are desirable for a successful treatment.  
When the OV is injected for treatment, it gets in contact with a variety of tissue types. In a selective process, 
a combination of viral tropism and innate immunity defines which cells can be infected. The virus attaches 
to specific host cells according to its own tropism and gets removed from some of these cells by the body’s 
“first line of defense”34, the IFN response. The presence of pathogens inside the body is recognized by 
pattern recognition receptors (PRR) to be found mainly on cells of the innate immune system such as 
dendritic cells (DC), macrophages and natural killer cells (NK cells), but as well on T and B Lymphocytes 
and non-immune cells, such as epithelial cells or fibroblasts 35. Among others, Toll-like receptors (TLR) 3, 7 
and 8 and retinoic acid inducible gene 1 (RIG-1) belong to the class of PRR. These receptors recognise highly 
conserved viral structures, known as pathogen-associated molecular patterns (PAMPS) 36, and induce a Type 
I IFN response 37. An infected cell with an intact IFN signalling pathway will react to viral infection with 
transcription of IFN-stimulated-genes (ISG) and translation of ISG-encoded proteins, leading to an antiviral 
state in the infected cell and neighbouring cells 38. This antiviral state is characterised by direct interference 
and reduction of viral replication through ISG-encoded proteins and an upregulation of MHC-I molecules 
on neighbouring cells. Early after infection, the circulating virus is inactivated by DCs, macrophages and NK 
cells that recognize PAMPS and engulf the virus via phagocytosis. However, once inside a host cell, the virus 
becomes invisible to cells of the innate immune system. MHC-I molecules, which display antigens from the 
inside on the cell surface to T cell receptors (TCR), become the identification mark for virus infected cells. 
Some viruses try to avoid recognition by downregulation of the production of MHC molecules. Those cells 
displaying down-regulated MHC molecules are destroyed by NK cells. Activated T cells and NK cells release 
cytotoxic factors that induce apoptosis in infected cells 14. CD8 is a co-receptor for MHC-I molecules on T 
cells and some NK cells. It activates T cells, when bound to viral antigen on MHC-I molecules, and the T 
cell matures into a CD8+ cytotoxic T cell. These kill the infected cell by granzyme-mediated induction of 
apoptosis or the extrinsic apoptotic pathway. Viral antigens that have been internalised by an antigen-
presenting cell (APC) are displayed in MHC-II molecules on the surface. These antigens can be recognised 
by CD4+ T helper cells, which activate other cells of the adaptive immunity. T cell receptors are additionally 
associated with the CD3 complex, that is necessary for signal transduction and amplification 39. Another 
component of adoptive immunity is the B-lymphocyte compartment. When a naïve, membrane-bound B 
lymphocyte gets activated by a pathogen and a helper T cell, it starts to differentiate into either a memory cell 
or an effector cell, which then produces soluble antibodies with the same receptor as the naïve B 
lymphocyte40. Effector cells mature into plasma cells and continuously secret antibodies, that inactivate a 
pathogen either by neutralization through binding to vitally important sites by agglutination, thereby creating 
clumps that are attractive for phagocytosis or marking pathogens for the complement system 41. 
Although tumor cells emerge endogenously and therefore do not carry exogenous antigens 42, there are innate 
and adaptive immune responses against cancer cells. This requires a discrimination between self-antigens and 
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altered-self-antigens 43.  Similar mechanisms as in pathogen eradication should also clear malignant cells from 
the system, but tumor cells, as well as many viruses, establish strategies for immune evasion. A process known 
as “immunoediting” describes immune evasion by random mutations during the high turnover in cancer cell 
proliferation. Mutations can, by chance be related to tumor antigens creating a heterogeneity that exhausts 
immune capacities and leads to clinical cancer. Other strategies include production or attraction of regulatory 
T cells as CD4+CD25+ that possess immune suppressive functions, productions of immune suppressive 
cytokines, such as TGF-β, TNF-α, CSF-1 and interleukins, and also downregulation of MHC-I molecules or 
expression of programed cell death 1 ligand 1 (PD-L1) 44. However, some of these modifications also allow 
an effective invasion of the tumor cells by the oncolytic virus. 
Tumor cells often show altered IFN pathways to impede lymphocyte function and thus be protected from 
immune recognition and to support tumor progression 15. One mediator for the impaired IFN function is 
the downregulation of RIG-I that can be found in HCC cells. This is moreover connected with a poor 
prognosis for the patient 45. Other studies suggest that an activated Ras/Raf 1/MEK/ERK pathway, which 
usually regulates gene expression and cell proliferation, leads to a defect in the IFNα-mediated response in 
about 30% of all cancers, many of them with limited therapeutic options46. Since IFN interferes with viral 
replication, these features allow an effective invasion of the tumor by the OV, leaving the surrounding tissue 
uninfected.  
2.5. Problems and Beneficial Effects of Immune Interference 
The previous sections outlined what powerful weapons OV’s can be in the fight against cancer and the 
immune reaction to viral infection as well as tumoral immune evasion. As a matter of fact, the immune 
response can be both, an enemy and ally for cancer treatment with oncolytic viruses. The viro-
immunotherapy approach attempts to overcome the obstacles to reinforce OV therapy with all the advantages 
of immunological interference.   
To begin with, the immune response in healthy cells is what makes the virus tumor-specific in the first place, 
but a very important factor in viro-immunotherapy is the limitation of viral efficacy because of the fast 
clearance by the immune system. This confronts the application of viro-therapy with a number of challenges 
that need to be addressed. For some viruses, e.g. vaccinia virus or measles virus, this might be a bigger threat 
than for others because of pre-existing immunity in human patients from vaccination programs. However, 
the use of animal viruses, that usually do not face pre-existing immunity in the general human population, 
still encounter the challenge of sufficient delivery to the tumor target. Although systemical application of viral 
vectors would be favourable to treat metastatic lesions, they tend to be cleared from the bloodstream before 
an effective amount of virus can accumulate in the tumor bed. Another problem that arises from a strong 
immune response is the limited efficacy of multiple-dosing-strategies due to the creation of virus-specific 
neutralizing antibodies47. There are attempts not only to evade immune cells to reach the tumor, but to use 
them as a transport vehicle. This allows the virus to stay hidden in an immune cell that can even be directed 
against tumor antigens and be transported safely to its target. When the OV reaches the tumor and 
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successfully invades the cell, it is capable of directly killing the cell. In so doing, it induces an immunogenic 
cell death, in contrast to the silent cell death a normal apoptotic cell undergoes, and tumor-associated antigens 
(TAA) derived from cell fragments are released. In this manner or by loading the virus with genetic 
information of TAA the virus is able to break immune tolerance and induce an anti-cancer immunity48. 
Additionally, the production of chemokines during viral infection can create an inflamed status in the tumor 
bed and attract immune cells for an anti-tumor response. Once an immune response is established, it is 
possible to treat the primary lesion, and potentially, metastatic lesions, and the production of memory cells 
could provide protective immunity against tumor rechallenges. As cancer cells are basically “self-cells”, a 
major concern for the treatment targeting a TAA is the induction of autoimmunity 49. It can be concluded, 
that it is an appealing idea to trigger the body’s own defense mechanisms to heal cancer, but it is necessary 
to find the right balance between the destructive and supportive power of immune interference. 
2.6. Parental Viruses 
2.6.1. Newcastle Disease Virus 
As a single-stranded RNA virus with negative polarity NDV is taxonomically classified in the order of 
Mononegavirales. Within this order it belongs to the family of Paramyxoviridae and as such it contains the 
genome structure typical for this virus family 50. The genus Avulavirus indicates the natural host of NDV, 
which is a wide variety of bird species. Its shape is spherical to pleomorphic and it has a size of 150-300nm 
51(Figure 1). 
 
 
Figure 1: Virion of Newcastle Disease Virus 
Spherical shaped virion consisting of viral envelope with integrated membrane proteins surrounding the 
nucleocapsid. The viral RNA, surrounded in a complex of nucleoprotein, phosphoprotein and large protein, 
comprise the nucleocapsid together with the M protein. 
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Source: Le Mercier, P.; Hulo, C.; Masson, P. (2010), [Avulavirus-Virion]. ViralZone-ExPASy, Retrieved 
17.01.2018, from https://viralzone.expasy.org/84?outline=all_by_species 
2.6.1.1. Epidemiology and Newcastle Disease 
The first reported outbreaks of this disease go back to Scotland in 1898, when high losses of poultry were 
observed while waterfowl appeared to be unaffected 52. Nowadays Newcastle disease is known to be endemic 
in many countries. While distribution via wild animals plays a minor role in spread of the virus, the main 
problem is trade with latently infected poultry, eggs or frozen products from poultry53. Once the virus is 
established in a herd, the main infection route is close contact to infected individuals or their feces36.An 
airborne infection by dust is also possible over short distances54. It appears as a disease with variable 
pathogenicity. In fact NDV strains can be categorized in one of the three pathotypes: lentogenic with no case 
of disease, mesogenic with intermediate pathogenicity and velogenic with severe pathogenicity 55. More than 
250 avian species are susceptible to NDV 56, but outbreaks of Newcastle disease gain most attention in 
infected poultry in which it can lead to severe symptoms and cause serious damage to the poultry industry. 
Virus shedding occurs via all secretions from infected birds and can additionally be passed on to chicken 
embryos by ovarian transfection.  Depending on the pathogenicity of the virus strain, the symptoms range 
from unapparent disease to reduced egg production, fever, gastrointestinal symptoms and respiratory 
symptoms to neurological symptoms and peri-acute death. In humans, there is a certain zoological potential 
with conjunctivitis and mild flu-like symptoms, but it is only reported in persons exposed to high virus 
concentrations, such as farm workers or veterinarians in close contact with infected material or individuals 
57. 
2.6.1.2. Genome and Viral Replication Cycle 
NDV’s genome consists of six genes (Figure 2) comprised of 15186 nucleotides in a highly preserved order. 
Like all paramyxoviridae, these genes encode the nucleocapsid protein (N), phosphoprotein (P), matrix 
protein (M), fusion protein (F), haemagglutinin-neuraminidase (HN) and large polymerase protein (L). 
 
Figure 2: Genome of Newcastle Disease Virus 
Negative sensed, single-stranded RNA genome of Newcastle Disease Virus. The six Genes N, P, M , F, HN and 
L in the highly preserved order. An mRNA editing step renders the possibility of expressing a V protein from 
the P gene.  
Source: Le Mercier, P.; Hulo, C.; Masson, P. (2010), [Avulavirus-Genome]. ViralZone-ExPASy, Retrieved 17.01.2018, 
from https://viralzone.expasy.org/84?outline=all_by_species 
These genes are interrupted by non-transcripted intergenic nucleotide sequences (junction sequences) whose 
purpose seems to be the creation of a transcription gradient. Each junction sequence has three sections, the 
gene-end section, intergenic section and gene-start section 55. With each junction sequence that the 
transcription machinery has to overcome, it is more likely to fall off the RNA-strand, and therefore proteins 
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on the 3’-end are much more often transcribed than proteins on the 5’-end. The production of continuous 
end-to-end antigenomic matrices is dependent on the amount of transcribed N protein, which prevents 
interrupted transcription at the gene-end section of junction sequences. These continuous matrices can finally 
be used as matrices for new virus genomes. A distinctive feature of the NDV genome is an RNA-editing step 
that integrates “non-templated G-residues” 55 into the P gene, which leads to the expression of an additional 
V protein. The V protein acts as Type I IFN antagonist via STAT1 degradation in infected cells and is crucial 
in highly virulent NDV strains 58. This antagonism is species-specific for avian cells lines and is an important 
determinant for the avian tropism of NDV. In human cell lines, NDV shows a strong IFN response 55.  
The viral attachment to a targeted cell is accomplished by the HN protein. HN possesses two binding sites 
for sialoglycoconjugates displayed on the host cells surface. Site I mediates receptor binding and sialidase 
activity, while site II acts as a binding-site only 59. Once HN binds sialic acids, the F protein can attach to the 
membrane and generate fusion of the viral envelope with the host cell membrane. The F protein exists as an 
inactive precursor (F0). After cleavage by host cellular proteases, the F protein splits into two active disulfide-
linked polypeptides (F1, F2)55. The hydrophobic N-terminus of the F1-subunit connects to the host cell 
membrane. The conformational change triggered by the F1- and HN binding mediates membrane fusion 50. 
In fact, the cleavage site of F is known to be responsible for the pathotype of NDV. Whereas lentogenic 
NDV strains have monobasic cleavage sites cleaved by proteases mostly found in the respiratory and digestive 
tract, velogenic strains have multibasic cleavage sites cleaved by ubiquitous proteases, which allows systemic 
infection 55. When the first steps, viral attachment and membrane fusion, are completed, viral RNA can enter 
the host cell cytoplasm where replication of the genome takes place. Here an RNA-dependent RNA-
polymerase (RdRp) complex, consisting of P protein and L protein, transcribes N protein-bound RNA into 
mRNA 60. The N protein coats RNA to prevent nuclease digestion. It shows two major domains. NCore, a N-
terminal region and NTail, a C-terminal region. NCore binds RNA while NTail mediates the connection between 
the N-RNA complex and the P protein 61. The P protein on the one hand leads to connection of the N-
protein-bound RNA and the RdRp complex and thus to transcription of the viral genome into mRNA. On 
the other hand, a complex of P protein and unassembled N monomers seems to lead to a switch from 
transcription to synthesis of progeny RNA 60. As already described above, junction sequences between 
structural genes create a transcription gradient in which proteins encoded in genes near the 3’-end are more 
often transcribed than proteins encoded near the 5’-end. This causes a high number of transcribed N 
monomers, needed for the switch to synthesis of continuous (-) RNA. This is necessary to form the genomes 
of the following generation of viruses. After protein translation by host cell ribosomes, assembly and budding 
of newly synthesized virus follows. For this purpose HN, F and N are transported to the host cell membrane 
where they accumulate. Interactions between P protein, N-RNA template and L protein form the 
nucleocapsid, and further interactions between the N and M protein incorporate the nucleocapsid into new 
virus particles 60.  
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2.6.1.3. Virus-Induced Apoptosis and Oncolytic Activity 
As a potent oncolytic vector, NDV can reliably kill tumor cells. Several studies revealed that NDV- infected 
cells undergo apoptosis showing typical signs such as “syncytium-formation, rounding and increased 
granularity” 62. A variety of direct and indirect mechanisms might be involved in this process, partly 
depending on the infected cell line and virus strain. The intrinsic and extrinsic apoptotic pathways seem to 
play a dominant role, but also ER stress pathways, receptor tyrosine kinase pathways and indirect mechanisms 
such as chemokine and cytokine release and thus, activation of the innate and adaptive immune response 55. 
 A study by Elankumaran et al. showed that induction of apoptotic cell death induced by NDV is independent 
of intact IFN signalling pathways. Moreover they conducted several experiments to gain insight into the 
importance of different apoptotic pathways in NDV-infected cells. Different NDV-infected cell lines showed 
different levels of TNF- α, but even the highest titers observed did not necessarily mediate apoptosis. A time 
course study of TRAIL showed that TRAIL mediated apoptosis is a late event and begins 14 h post infection 
(p.i.). TNF- α and TRAIL are members of the death receptor family. Together with the Fas-associating 
protein and proximity of caspase-8, they mediate the extrinsic apoptotic pathway. Caspase-8 was shown to 
be activated rather late at 48 h p.i. in some tumor cell lines, and there was no caspase-8 activation in colorectal 
cancer cell lines (CaCo2, HT29). Therefore, caspase-8 seems to be activated, but not the initiator of apoptosis. 
Investigation of the intrinsic apoptotic pathway by localization of cytochrome c after a drop in mitochondrial 
membrane potential in NDV-infected cells showed a two-fold increase of cytochrome c in the cytosol. 
Additionally, there was no activation of inhibitors of apoptosis, but rather, a caspase-9 activation with 
significant levels 6 h p.i. It can be summarized that NDV infection leads to a destabilization of mitochondrial 
membrane potential and activation of caspases-9 and -3 and thus to an activation of the intrinsic apoptotic 
pathway. Subsequently, caspase-8 and the extrinsic pathway are also activated 62. Furthermore, sequencing of 
NDV’s genome indicated the existence of pro-apoptotic Bcl-2 homology-3 (BH3) domain-like regions in the 
M, F and L protein 55, which can be activated by caspase-3 and induce the intrinsic apoptotic pathway. 
Indirect induced tumor cell killing is accomplished by activation of innate and adaptive immune responses. 
Infection of murine macrophages with NDV showed enhanced production of macrophage enzymes and 
TNF-α 55. Monocytes were able to induce apoptosis in tumor cells by activation of TRAIL after infection63, 
and NK cells stimulated with NDV showed enhanced cytotoxicity against tumor cells55. In fact, NDV-HN 
is known to have powerful immunogenic effects, making HN a valuable component for antitumor vaccines 
64.  
2.6.1.4. Genetically Engineered NDV as Anti-Cancer Agent 
Since the early 1990’s, when recombinant DNA technology became a laboratory standard and genetical 
engineering of viruses a reasonable perspective, research in this field started its second upturn 1. The number 
of newly designed OVs that address specific problems from virus delivery to decreased toxicity to altered 
efficacy, increases from year to year. 
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Concerning NDV, various modifications have been engineered to enhance to its properties as an oncolytic 
agent. Some attempts deal with the enhancement of NDV virulence. The more virulent the strain, the more 
effective its intratumoral spread, replication and apoptosis. Thus, higher virulence correlates with improved 
oncolytic properties of NDV, making velogenic and mesogenic strains lytic in human cancer, whereas 
lentogenic strains are often classified as non-lytic in human cancer55. As explained above the cleavage site in 
the F-protein (monobasic in lentogenic strains and polybasic in velogenic strains) determines the virus’s 
pathogenicity. Building on this, lentogenic NDV Hitchner B1 strain was engineered with a polybasic cleavage 
site in the F-protein (F3aa), and an additional point mutation at base pair 289 in the F protein from leucine 
to alanine (L289A) was introduced to enhance fusogenicity. The result is rNDV/F3aa (L289A), which results 
in enhanced oncolytic effects in vitro and in vivo65. In vitro, a significantly higher syncytial index in HCC and 
normal cell lines could be observed in cells treated with rNDV/F3aa (L289A) compared to rNDV/F3aa 
(Figure 3). In vivo treatment led to only mild and transient body weight loss and alteration of liver enzymes, 
which returned to normal by day three after injection. Moreover an increase in tumoral necrotic areas was 
observed, as well as a prolonged survival in HCC-bearing rats. Two animals in the rNDV/F3aa (L289A)-
group even showed complete tumor regression 65. Another step in the same direction is a study by Park et 
al., where the anti-tumor activity of IFN-sensitive NDV Hitchner B1, modified to express a mammalian IFN-
antagonist, the NS1 protein from Influenza A, was investigated66. Their hypothesis, a repressed immune 
response would support viral replication and intratumoral spread, could be confirmed in human and mouse 
melanoma cell-lines. A comparison showed that NDV(F3aa)-NS1 is as effective as its parental virus 
NDV(F3aa). At low MOIs it appears to be more effective than NDV(F3aa). In vivo studies on melanoma-
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bearing mice treated with NDV(F3aa)-NS1 confirmed a decelerated tumor growth compared to NDV(F3aa) 
and PBS 67. 
 
Figure 3:  AGE1.CR pIX cells forming syncytia from NDV/F3aa (L289A) infection 
Photo microscopy of AGE1.CR.pIX cells infected with NDV at an MOI of 0.001 and 48h after infection. 
Images were captured under 100x magnification. 
The idea of NDV expressing apoptin, a proapoptotic protein from chicken infectious anemia virus provides 
another strategy to improve the oncolytic effect, but is potentially problematic. Experiments with this 
recombinant NDV strain demonstrated that high MOI’s are necessary to improve induction of apoptosis 
compared to the parental virus. Also this treatment results in an early cell death of the host cell, which impedes 
multi-cycle replication and further spread of the virus into the tumor tissue 68. 
Another exciting approach is to arm the viral vector with immune agents such as cytokines or complete 
antibodies. An in vitro study with NDV expressing human IL-2 showed stimulation of T-cells in a tumor-
neutralization assay. Moreover, an increased expression of activation marker CD69 and increased production 
of IFN-γ was noted. In vivo experiments in mice with subcutaneously implanted colon carcinoma indicated a 
clear advantage of rNDV/F3aa-IL-2 over rNDV/F3aa, with a drastic reduction in tumor size and partial and 
long-lasting remission. Mice that underwent complete tumor regression were furthermore protected from 
ongoing tumor challenge 69. Pühler and colleagues demonstrated that it is possible to integrate two transgenes 
into the genome of mesogenic NDV-MTH68, leading to expression of a complete monoclonal antibody 
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(rNDV-MTH146). The transgenes have been inserted between NDV-F and NDV-HN and encode the heavy 
and light chain of immunoglobulin G (IgG) directed against the extradomain-B of fibronectin (ED-B 
fibronectin), a tumor specific antigen. In vitro experiments demonstrated that rNDV-MTH146 does not 
impede viral replication or tumor selectivity. Indeed only tumor  cells were able to produce functional 
antibodies after infection and also cell lysis has only been observed in tumor cells 70. 
A very promising approach is to employ an OV carrying tumor antigen in a vaccination scheme to mediate 
an immune response against the tumor. NDV vectors expressing tumor-associated antigens (TAA) have been 
used in this regard. The same group that worked with NDV expressing human IL-2, designed rNDV/F3aa-
minigal, an NDV encoding for a β-gal-specific CD8+ T cell epitope. Experiments conducted in vivo confirmed 
the importance of specific T-cell responses as a means to attack the tumor. They treated tumor-bearing nude 
mice, with a known deficiency of T cells, and immunocompetent BALB/c mice with PBS, rNDV/F3aa-IL-
2 or rNDV/F3aa-minigal. Their results showed no survivors in the T cell-deprived mice but a clear survival 
benefit in both virus treated immunocompetent groups. A combination therapy of both recombinant viruses 
however showed tumor regression in 90% of the treated mice compared to 50% in r NDV/F3aa-minigal 
injected mice71. 
Considering the endless number of possibilities recombinant oncolytic viruses provide for cancer therapy it 
is a promising path for future research in this field. It is clear now that NDV is a potent oncolytic viral vector 
with no severe toxicity concerns in mammalian species, but there is a risk of treated patients shedding a low 
amount of virus, thereby creating an environmental risk 72. Previous studies indicated that mesogenic and 
velogenic strains are more effective as anti-cancer agents. However, this poses a substantial risk of an outbreak 
of disease among bird populations, and could jeopardize the poultry industry. In fact, this problem put 
virulent NDV strains on the list of “USDA select agents and toxins” severely limiting the further development 
of NDV for clinical application. 
2.6.2. Vesicular Stomatitis Virus 
VSV like NDV, is a non-segmented, negative-sense RNA virus, and as such, in the order of Mononegavirales. 
It is classified in the family of Rhabdoviridae and genus Vesiculovirus. It comprises a broad host range, 
including vertebrates, as well as insects and plants. The two major serotypes, VSV-Indiana (VSV-IN) and 
VSV-New Jersey (VSV-NJ), infect horse, cattle, swine, mosquitos and sandflies. VSV has the distinct bullet-
shaped profile, characteristic for the virus family73, and a size of 70x200nm74. The nucleocapsid consists of 
the viral RNA that lays surrounded tightly by up to 1200 molecules of N protein and fewer L and P proteins 
in a helical complex coated in a layer of M protein (Figure 4). The viral envelope is made of a phospholipid 
bilayer from the host cell, which is left on the virus after budding, and trimers of Glycoprotein (G protein) 
build spikes on the outside of the lipid membrane 75. 
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Figure 4: Virion of Vesicular Stomatitis Virus 
Bullet-shaped virion of VSV. The envelope equipped with trimers of G protein surrounds the nucleocapsid. 
Viral RNA and the nucleoprotein are combined as ribonucleoprotein core. Accompanied by L, P and M protein 
they build the nucleocapsid. 
Source: Le Mercier, P.; Hulo, C.; Masson, P. (2010), [Avulavirus-Genome]. ViralZone-ExPASy, Retrieved 
17.01.2018, from https://viralzone.expasy.org/84?outline=all_by_species 
2.6.2.1. Epidemiology of Vesicular Stomatitis 
VSV was first reported as a disease in 1916 in the US. In retrospect, it might also have occurred in 1862 
during the US Civil War in army horses. VSV-IN and VSV-NJ are enzootic in North-, Central and South 
America, and outbreaks have been reported occasionally until 1995 73. In cattle, horses and swine VSV causes 
vesicular stomatitis, a disease accompanied by fever and vesicles on the oral mucus membrane, feet and teats. 
Transmission of VSV is accomplished by infection via arthropods, or direct contact to infected material, such 
as water, food or milking machines 76. Other than a decrease in productivity of infected animals, the disease 
results in low mortality rates. The main problem with VSV infections is its clinical similarity to Foot and 
Mouth Disease, which is on the OIE list of notifiable diseases (OIE listed diseases, 2018). VSV-IN and VSV-
NJ possess a mild zoonotic potential. Infections can lead to flu-like symptoms in humans. Another 
vesiculovirus, Piry virus, causes mild symptoms with headaches, myalgia and arthralgia over three to four 
days and is endemic in Brazil. Also common in Africa and Asia, is Chandipura virus. In India, there is a high 
prevalence of animals in different species infected with Chandipura virus. It is also known to be zoonotic 
and the symptoms are similar to Piry virus infection, besides one reported case of encephalitis caused by 
Chandipura virus in an eleven-year-old indian girl 77.   
2.6.2.2. Genome and Viral Replication 
As NDV and VSV are both in the order of Mononegavirales there are striking similarities in their genome 
structure and replication. VSVs genome has five genes composed of 11000-12000 nucleotides encoding five 
proteins, the N protein, P protein, M protein, G protein and L protein (Figure 5). Throughout the 
Mononegavirales, all viruses are transcribed by sequentially interrupted mRNA synthesis, leading to a 
transcription gradient78 as described for NDVs “Genome and Viral Replication Cycle”.  
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Figure 5: Genome of Vesicular Stomatitis Virus 
The negative sensed, single-stranded RNA encodes 5 genes: the Nucleoprotein (N), phosphoprotein (P), matrix 
protein (M), glyco protein (G) and large protein (L).  
Source: Le Mercier, P.; Hulo, C.; Masson, P. (2010), [Avulavirus-Genome]. ViralZone-ExPASy, Retrieved 
17.01.2018, from https://viralzone.expasy.org/84?outline=all_by_species 
One advantage that makes VSV a favoured OV is its ability to enter a broad range of cells, giving VSV a 
pantropic infectivity. Viral attachment and entry are performed by the G protein. Finkelsthein et al. conducted 
an experiment in which soluble low density lipoprotein receptor (LDLR) completely inhibited entry of VSV 
into the host cell by binding to the virus or a cellular VSV receptor, when given before VSV challenge or at 
the same time. The results indicated that the LDL receptor is the major entry receptor for VSV on the host 
cell surface. The ubiquitous expression of the LDLR family on various cells also explains the broad tropism 
of VSV 79. Although VSV is an extensively investigated virus, there are still parts of the entry process, which 
are not yet clarified. It is known that the trimeric associated G proteins on the virus surface mediate viral 
attachment, as they bind to LDL receptors. This leads to endocytic internalization of VSV via the clathrin-
mediated endocytic route 80. The acidic milieu inside the endosome triggers a conformational change of the 
G protein at a pH in the range between 6.2 and 5.0. Each monomer in the VSV-G trimer has a tertiary 
structure that allows the division into four domains (I-IV). Of these, domain IV is the fusion domain, which 
contains fusion peptides on two internal loop regions. With increasing acidity of the endosomal milieu, the 
G protein becomes more hydrophobic, and the fusion loops penetrate the endosomal membrane leading to 
fusion with the viral envelope 75. After viral fusion is completed, the nucleocapsid can enter the cytoplasm of 
the host cell, where VSV replicates. Transcription is accomplished by the RNA-dependent RNA polymerase 
(RdRp) complex consisting of P and L protein. N protein-coated RNA serves as a template for this complex. 
Transcription begins with synthesis of a plus-strand leader-RNA whose purpose is still unknown 81. As 
already described in section “Newcastle Disease Virus”, mRNA of the five genes is synthesized following a 
transcription gradient caused by intergenic sequences that interrupt the process of translation. The number 
of copies of each proteins in each nucleocapsid illustrates that different proportions of proteins are required 
for the construction of a new virion. In a completed nucleocapsid are 1250 copies of N, 470 copies of P and 
only 50 copies of L, as it is transcribed the least. The RdRp complex also functions as a capping enzyme for 
mRNA and caps during mRNA synthesis and polyadenylates when reaching the termination-sequence 
AUACU7 at the end of a gene. In this way, the five genes are transcribed, capped and polyadenylated before 
release from the transcription complex. The switch from transcription of mRNAs to transcription of a full-
length genome with positive polarity, which can be used as a template for progeny RNA, is again dependent 
on the presence of N protein. M protein may also play a role in the regulation of mRNA synthesis 82. At early 
points in time during replication, newly synthesized nucleocapsids are distributed in clusters in the perinuclear 
region. Transport of the viral components to the cell membrane, where budding takes place, is accomplished 
via active transport by actin filaments as well as microtubules 83. The G protein, is transported first into the 
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endoplasmic reticulum for glycolysation and then transported to the cell membrane 82. Near plasma 
membranes, selected nucleocapsids and free cytosolic, as well as membrane bound M protein form a 
nucleocapsid-M protein complex 73. M protein acts hereby as an adaptor between G protein present on the 
host cell membrane and nucleocapsids on the inside and, therefore, mediates budding of new virions from 
an infected cell into neighboring cells 82. Progeny viruses are internalized into neighboring cells via 
endosomes, which they enter again after acidification of the endosome 84. Compared to other viruses, VSV 
has a very short replication cycle and first assembly of progeny occurs at approximately 2-3h post infection 
5. 
 
 
Figure 6: AGE1.CR pIX cells showing CPE and GFP expression after infection with VSV-GFP 
Photo microscopic picture of AGE1.CR.pIX cells expressing GFP at 18h after infection with rVSV-GFP at on 
MOI of 0.01. The picture was captured under 100x magnification. 
2.6.2.3. VSV Induced Oncolytic Activity and Neurotoxicity 
VSV is known to be a potent oncolytic agent, and an important aspect of the cell lysing activity is the M 
protein 85. Its natural purpose is to impede cellular gene expression and thus prevent antiviral activity, such 
as IFN production. It inhibits export of mRNA from the nucleus by interference with two important proteins 
of the mRNA export machinery, Rae1 and Nup98. These proteins also play an important role in spindle 
assembly during mitosis. Rae1 is a Ran-regulated factor for spindle assembly. It is crucial in formation of 
organized microtubules in the nucleus to form the spindle apparatus. Nup98 can enhance binding between 
Rae1 and importin β 86, which is a regulator of Ran-dependent spindle assembly factors 87. M protein interacts 
with a Rae1-Nup98 complex, which impedes formation of a functioning spindle in mitotically active cells, 
leading to cell death during metaphase. As tumor cells have high mitotic indices, they preferentially undergo 
cell death when infected with VSV, as compared to normal cells85. This feature keeps infected cells from 
alerting the immune system and is, together with the fast replication cycle, responsible for the high production 
yields of VSV in infected cells. Another mechanism involved in VSV-induced cell death is the induction of 
the intrinsic pathway of apoptosis by caspase-9 activation 88.  
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That an intact IFN response in healthy cells is an effective instrument against viral infection is impressively 
shown in the central nervous system (CNS), where VSV infection leads to neurological symptoms and death 
at comparatively low virus titers. Neurons are highly developed cells with high metabolic rates and at the 
same time a very low capacity for regeneration. Virus induced cell death has much more impact in this isolated 
environment and is tolerated less than in regenerative tissues. Another component that increases the effect 
on infected cells of the CNS is the blood brain barrier. Once a virus overcomes this security mechanism that 
allows entry only to selected components of the blood stream (gases, glucose, substances with high lipid 
solubility 89), they are effectively shielded from immune functions of the peripheral immune system as well. 
Detection of viral infections is all the more difficult as there is no expression of MHC-I molecules in the 
brain and also MHC-II molecules can only be found on microglia and astrocytes, dependent on TNFα and 
IFN-γ, which are not present at early stages of viral infection in the CNS 90. If present, inflammatory cytokines 
from infected glial cells can induce encephalitis 16.These conditions emphasize why VSV can lead to severe 
neurotoxicity accompanied with paralysis and excitability in immunocompetent Buffalo rats at doses higher 
than 1x107 PFU administered via the hepatic artery 91.  
2.6.2.4. Geneticallly Engineered VSV 
Again, there are several recombinant versions of the wild type virus designed to either enhance oncolytic 
abilities, diminish safety concerns or add completely new features to the viruses repertoire.  
Many of these strategies aim to improve the profile for safety and oncoselectivity. There have been studies 
with VSV expressing mutant versions of the M protein to prevent healthy cells from being defenseless against 
viral infection. As the M protein effectively inhibits cellular transcription and RNA transport from the nucleus 
into the cytoplasm, it is potentially cytotoxic even in a healthy cell. The idea is that recombinants with a 
mutant M protein can still replicate productively in tumor cells, which are defective in the IFN pathway, and 
at the same time can be cleared by normal cells. Studies with rVSV*MQG133, which is VSV with a mutant M 
protein and fusion-defective G protein showed enhanced IFN production in vitro compared to rVSV-GFP 
and continuing propagation of infected Vero cells 92. Experiments conducted in vivo in immunocompetent, 
tumor-bearing mice showed that treatment with rVSV-M(mut)-mp53, a VSV with mutated M protein and 
murine tumor suppressor, p53, even led to elevated titers of antitumor CD8+ T cells, which makes this 
recombinant an attractive candidate for viro-immune therapy 93. 
Another approach is alteration of the VSV G protein. In rVSV-CT1 and rVSV-CT9-M51, the G protein has 
deletions in the cytoplasmic tail reducing it from 29 amino acids to 1 and 9 amino acids, respectively. rVSV-
CT9-M51 has additionally a deletion of the amino acid at position 51 in the M protein (methionin). Both 
recombinant viruses are attenuated compared to rVSV-GFP and show a much better safety profile. Intraceb-
ral injection of the viruses into immune competent 16-day-old mice showed significantly prolonged survival 
in the rVSV-CT9-M51 group. Both attenuated viruses also led to reduced neuroinvasion compared to rVSV-
GFP after intranasal inoculation, with survivors showing no neurological symptoms. rVSV-CT9-M51 also 
retained its oncolytic abilities in multiple human and rodent tumor cell lines in vitro 94. 
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Furthermore, there are recombinant VSV vectors in which the entire G protein is replaced by glycoproteins 
derived from other viruses for retargeting viral attachment. Muik et al. created a VSV recombinant, which 
expresses the glycoprotein of lymphocytic choriomeningitis virus (rVSV-LCMV-GP). This recombinant, 
when injected systemically in immunocompetent mice, has shown no neurotoxicity even at high doses (109 
PFU). rVSV-LCMV-GP remained oncolytic as shown in vivo in immunodeficient mice, where both viruses, 
rVSV-LCMV-GP and rVSV-GFP, led to effective tumor regression. Although while a majority of rVSV-
GFP mice died from neurotoxicity, even when the virus was administered intratumorally at low doses (2x105 
PFU), rVSV-LCMV-GP-treated mice survived without signs of illness. An additional advantage provided by 
the glycoprotein exchange in this case, is a reduced response from the humoral immunity against the virus, 
which allows multidose regimens for tumor treatment 95.   
The attempt to integrate thymidine kinase (rVSV-TK) into VSVs genome and treatment in combination with 
the prodrug ganciclovir also had significant effects on subcutaneous tumor growth when administered 
intratumorally in melanoma or mammary tumors. Following the treatment, also an uptake of antitumor 
cytotoxic T cell activity was also shown, which adds an immunotherapeutic feature to the treatment 96. 
Other recombinants exploit the viro-immune therapy approach. There are VSV vectors expressing INF-β to 
support antiviral defense in non-malignant cells 97, 98 and VSV expressing interleukins 4, 12 and 23 as 
immunomodulatory therapies 96, 99, 100. These treatments aim at an enhanced antitumor immune response. 
An alternate approach is to suppress immune responses in order to give the virus time for replication and 
intratumoral spreading before being cleared by the immune system. This is accomplished by rVSV-gGEHV-1 
which expresses the glycoprotein of equine herpes virus (EHV-1). It acts as a viral chemokine binding protein 
(vCKBP) and was shown to enhance intratumoral viral replication, tumor necrosis and prolonged survival of 
immunocompetent rats bearing HCC101. 
Here again recombinant viral vectors provide an infinite number of possibilities for cancer treatment. What 
remains to be proven, is an efficient and long-lasting effect in vivo of recombinants without neurotoxic 
component, ideally when given intravenously to reach inoperable tumors as well as metastases. 
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3. The Pseudotyped Vesicular Stomatitis Virus: rVSV-NDV 
3.1. Construction of rVSV-NDV 
rVSV-NDV is a combination of the viruses VSV and NDV. As its parental viruses, VSV-NDV is a single 
stranded RNA virus with negative polarization. The genome consists of six genes encoding six proteins. Four 
of them, the N, P, M and L protein are derived from the VSV genome. Proteins F and HN from the NDV 
genome replace the attachment protein G (Figure 7). 
 
Figure 7: Genome of VSV-NDV 
Illustrated is the construction of recombinant VSV-NDV vector from its parental virus genomes, NDV (red) 
and VSV (yellow). The envelope proteins, F and HN, from NDV are integrated into the genome of VSV. The 
negative sense, single-stranded RNA of VSV-NDV encodes 6 genes: the nucleoprotein (N), phosphoprotein (P), 
matrix protein (M), large protein (L) from VSV and the fusion protein (F) and hemagglutinin-neuraminidase 
(HN) protein from Newcastle disease virus. 
For this modification we postulate several advantages. The deletion of the VSV-G protein and replacement 
by NDV-F3aa(L289A) and –HN addresses the problem of neurotoxicity associated with wild type VSV 
(wtVSV). In contrast to VSV-G, that allows entry and replication in a large number of tissues in nearly all 
species including neurons of rodents and non-human primates 102, the safety profile of NDV as an oncolytic 
agent in clinical trials is very promising. With flu-like symptoms, tumor-site-specific adverse events and acute 
dosing reactions, human patients in phase I clinical trials reacted comparatively well to NDV treatment. 
Further experiments conducted to prove this hypothesis are shown in section “Preliminary Data”. 
Moreover, rVSV-NDV is not expected to lead to any toxicity in birds. The NDV strain used to create rVSV-
NDV is NDV/F3aa(L289A), a mesogenic NDV strain. It is shown that the NDV-HN, - F and -P protein 
can individually or collectively take part in the pathogenicity of NDV. A study conducted with the lentogenic 
NDV strain LaSota, the velogenic NDV strain Beaudette C and several recombinants of those (e.g. LaSota 
expressing a virulent F cleavage site rLaSoVF, Beaudette C experessing a low virulent HN protein 
rBCLaSoHN or La Sota expressing a virulent HN protein rLaSo BCHN) investigated the influence of the 
named proteins in NDVs virulence. Among other things, the results showed that both a virulent F-cleavage 
site and HN from a virulent strain are required to achieve high virulence and severe diseases 103.  Additionally 
the recombinant rVSV-NDV does not include the NDV-P protein, therefore no expression of the V protein 
is possible either. As the V protein acts as a species-specific IFN-antagonist in avian species, the absence of 
the V protein significantly diminishes viral replication in vitro and in vivo in embryonated chicken eggs58. 
According to these findings the integration of F and HN from a mesogenic strain into the genome of VSV 
26 
and deletion of the P protein could maybe even impede the virulence in birds compared to the 
NDV/F3aa(L289A) strain. 
One last advantage of rVSV-NDV over VSV is its ability to fuse infected cells into multi nucleated giant cells 
(syncytia) and spread effectively inside the tumor tissue (Figure 8). Additionally, by syncytia formation, the 
virus avoids humoral immune responses as the virus spreads predominantly inside the tumor mass 84 and 
potentially leads to an extended time span between infection of tumor cells and clearance by the immune 
system. While the virus evades an immune response inside these giant cells, it is at the same time a more 
immunogenic cell death than silent apoptosis, leading to an antitumor immune response through activation 
of dendritic cells and tumor-specific T cells104. Experiments have also been  conducted with rVSV-NDV/F 
(L289A) 84, a construct that contains the endogenous VSV glycoprotein in addition to a mutated NDV-F 
protein, which is fusogenic even in the absence of the hemagglutinin-neuraminidase. These results showed 
intratumoral syncytia formation in rats bearing orthotopic HCC, treated with rVSV-NDV/F-(L289A) as soon 
as on day one after treatment. Also survival of rVSV-NDV/F-(L289A)-treated rats was significantly 
prolonged. 
 
Figure 8: AGE1. CR pIX cells forming syncytia and expressing GFP after infection with VSV-NDV-GFP 
Photo microscopic picture of AGE1.CR.pIX cells 18h after infection with VSV-NDV at MOI 0.01. The picture 
was captured at 100x magnification. 
3.2. Preliminary Data 
VSV-NDV has already been characterized in vitro. Crucial features that rVSV-NDV should provide in order 
to be a safe OV are a strong replication in tumor cell lines and a reliable inhibition by healthy, IFN producing 
cells. It was first investigated for its replication and syncytia induction abilities in human HCC cell lines. The 
results show that rVSV-NDV replicated to similar titers as the parental viruses at 72 hours after infection 
although under microscopic surveillance (Figure 10) infection of rVSV-NDV treated cells appeared more 
rapid than the growth curve (Figure 9) indicates. These results are consistent with the data derived from a 
lactate dehydrogenase (LDH) cytotoxicity assay. Here again, complete cytotoxicity was reached after 72 hours. 
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Figure 9: Growth curve and cytotoxicity assay in an HCC cell line (HepG2) 
Growth curve and LDH assay were conducted on human HCC cell lines HepG2. Cells were infected at an MOI 
of 0.01 of rVSV, rNDV or rVSV-NDV. One hour after infection cells were washed and medium was replaced 
by fresh medium. At various time points after infection aliquots of the supernatant were taken and used for 
LDH cytotoxicity assay. Cells were harvested and used for TCID50 assay. Experiments were performed in 
triplicates and are presented as mean +/- standard deviation. 
To confirm that rVSV-NDV can still induce syncytia formation in HCC cell lines, Huh7 cells were infected 
with rVSV-NDV and compared to rNDV and rVSV infected cells at different points in time after infection. 
A non-infected PBS group was used as control. Here, syncytia formation was first detectable in the rVSV-
NDV treated group at 16 hours after infection, whereas NDV-treated cells showed first signs of syncytia at 
24 hours after infection. VSV-infected cells showed typical CPE already earlier than 16 hours after infection, 
but as expected, no syncytia formation. 
 
Figure 10: Photo microscopic comparison of HCC cells infected with rVSV-NDV, NDV and VSV 
Human HCC cells, Huh7, were infected at an MOI of 0.01 with rVSV-NDV, NDV and VSV and observed over 
48 hours. Here we see a comparison between the different virus-infected groups at representative points in time. 
Images were captured under 200x magnification.  
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As a selective oncolytic agent, rVSV-NDV is not expected to replicate in non-malignant tissues. To investigate 
the replication behaviour of rVSV-NDV in the tumor surrounding tissue, primary human hepatocytes were 
infected with rVSV-NDV and compared to its parental viruses rVSV and rNDV. The results confirm that 
rVSV-NDV is clearly less replicative in primary human hepatocytes in contrast to both VSV and NDV 
especially at later points in time around 24 hours after infection (Figure 11, left). Similar results were obtained 
with an LDH assay. Here no evidence of cytotoxicity in rVSV-NDV treated cells was found (Figure 11, right). 
 
Figure 11: TCID50 and LDH assay of primary human hepatocytes infected with rVSV-NDV, rVSV and rNDV 
Primary human hepatocytes were infected with rVSV-NDV, rVSV and rNDV at an MOI of 0.01. Cell lysates 
were used to perform TCID50 at different points in time after infection. Aliquots of the supernatant were 
collected at different points in time and used for LDH assay. Experiments were performed in triplicate, and 
means +/- standard deviation are shown. 
An important requirement of rVSV-NDV as a tumor-specific oncolytic agent is a good responsiveness to 
type I IFN. To make sure that healthy cells are protected from the virus by their natural defense mechanisms 
and only tumor cells are successfully infected, rVSV-NDV was tested in an IFN dose response assay and 
compared to its parental viruses. As rNDV appeared to be almost unresponsive, both rVSV and rVSV-NDV 
show an effective decrease in viral titers under IFN treatment (Figure 12). 
 
Figure 12: IFN dose response of rVSV-NDV compared to rVSV and rNDV 
For this assay, an IFN sensitive cell line A549 was infected with rVSV-NDV, rVSV and rNDV at an MOI of 0.01. 48 
hours after infection cells were lysed and used for viral titer measurement by TCID50. This experiment was performed 
in triplicates and mean values +/- standard deviation are shown. 
  29 
To confirm that cells of the nervous system are not susceptible for rVSV-NDV, and therefore no 
neuropathological side effects are expected, replication in primary, embryonic rat neurons was measured by 
TCID50 and once again compared to rVSV and rNDV. Here, the titer of VSV increases by almost six logs 
within 16 hours after infection, while the titer of rVSV-NDV is five logs lower at the same point in time 
(Figure 13, left). Similar results were obtained in an MTS assay. Whereas the viability of rVSV-treated cells is 
already diminished by 50% at 24 hours after infection, rVSV-NDV and rNDV show comparable results with 
nearly 100% viable cells (Figure 13, right). 
 
Figure 13: TCID50 and MTS assay in primary rat neurons infected with rVSV-NDV, VSV and NDV 
Primary rat neurons were infected with rVSV-NDV, rVSV and rNDV at an MOI of 0.01 to perform TCID50 and a 
standard MTS assay at various time-points post-infection. Cell lysates were used to measure viral titers with TCID50. 
Cell monolayers were used for the MTS assay. Experiments were performed in triplicate, and means +/- standard 
deviation are shown. 
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4. Aim of the Project 
In this study the newly created recombinant virus, rVSV-NDV was investigated for its efficacy and safety in 
vivo. To evaluate these parameters, experiments were conducted in immune-deficient NOD-SCID mice, as 
well as in immune-competent AST mice and Buffalo rats. Characteristics of interest were safety, viral 
shedding, the potential to induce an antitumor immune response, development of neutralizing antibodies, 
cross-reactions to neutralizing antibodies for parental viruses and survival benefit of treated animals. 
Experiments on viral toxicity were performed in NOD-SCID mice. This animal model allows investigation 
regarding viral toxicity using only low virus titers. Furthermore, an immunodeficient animal model provides 
a more powerful test on neuropathogenicity as neurotoxicity is a major concern for VSV derived viruses. 
Viral shedding and survival experiments were performed in immune-competent animal models. Since an 
important part of cancer treatment with oncolytic viruses is maintained through enhanced anti-tumor 
immune responses, the necessity of an immune-competent model is obvious. To test the benefit of the 
treatment on the therapeutic outcome, two animal models with a different focus on translation were chosen. 
One of them was a mouse model with the benefit of a highly translational, inducible HCC. The second was 
a rat model with implanted HCC and allows for a semi-selective and more translational virus delivery route. 
As the mouse model results in multifocal HCC nodules, intratumoral injection of virus is not really feasible, 
and systemic application via tail vein is more appropriate. In the rat model the size of the animals allows for 
injection into the hepatic artery, which supplies about 85-100% of the tumoral blood flow 105. This injection 
route mimics the application of transarterial chemoembolization (TACE) in patients and gives the 
opportunity to inject the virus in close proximity to the actual tumor site and reduces inactivation of the virus 
by unspecific immune responses. The state of the art method for OV application in cancerous diseases is 
intratumoral injection. As the OV is injected directly into the tumor, this method offers the advantage of 
minimal immune responses against the virus before it has the opportunity to enter the cells. In order to mirror 
the possibilities of clinical treatment completely, we also performed intratumoral injection in Buffalo rats 
with implanted HCC, because currently only unifocal tumors can be treated using this application route. 
In the controlled environment of the implanted tumor model in rats, experiments on viral kinetics were 
performed. These experiments included evaluation of neutralizing antibody induction, analysis of an 
antitumor immune response by tumor cell-PBMC co-culture and flow cytometric analysis of T cells and 
tumor cells, as well as measurement of viral titers in tumor, liver and brain of treated rats at different points 
in time after treatment.  
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5. Material and Methods 
5.1. Cell Lines and Culture 
All cell lines used were adhesive cell lines. AGE1.CR.pIX cells (obtained from ProBioGen AG, Berlin) were 
used for virus production and measurement of viral titers. Cells were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) and nutrient mixture F12 supplemented with 5% fetal calf serum, 1% penicillin-
streptomycin and 1% L-glutamine. The rat Morris Hepatoma 7777 cell line (McA-RH7777) was used for 
implantation of HCC in the liver of syngeneic Buffalo rats. Cells were maintained in high-glucose ATCC®- 
DMEM supplemented with 10% fetal calf serum and 1% Penicillin-Streptomycin. When T cells were 
involved in experimental use, they were kept in Rosewell Park Memorial Institute (RPMI) medium 
supplemented with Penicillin-Streptomycin, 1% non-essential amino acids and 1% sodium pyruvate 
(100mM). All cell lines were incubated at 37°C and with 90% humidity and 5% CO2.  
Table 1: Reagents Used for Cell Culture  
Reagents Company 
DPBS PAN Biotech 
FBS Superior Merck 
L-Glutamine PAN Biotech 
Penicillin-Streptomycin PAN Biotech 
Trypsin/EDTA PAN Biotech 
DMEM-F12 biowest 
DMEM High Glucose ATCC 
RPMI 1640 biowest 
Antibiotics/Antimycotics Gibco® 
 
Table 2: Consumables Used for Cell Culture 
Consumable Company 
75cm2 Cell Culture Flask Sigma-Aldrich 
96-well Plate Sigma-Aldrich 
150cm2 Cell Culture Dish Sigma-Aldrich 
Eppendorf Tubes /Safe Lock Tubes Eppendorf 
Reax top, tube shaker Heidolph 
100-1000µl pipet Eppendorf Research plus 
20-200µl pipet Eppendorf Research 
2-20µl pipet Eppendorf Research 
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0.5-10µl pipet Eppendorf Research 
Tip One RPT, Pipet tip 10µl RNase, DNase, 
DNA and Pyrogen free 
StarLab 
RPT Filter tips, 20µl StarLab 
Universal Fit Pipet Tips, 200µl Corning 
Filter tips, 1000µl Clear Line 
Ultra pipet controler Corning Stripettor™ Ultra 
serological pipet, 5ml Greiner bio-one 
serological pipet, 10ml Greiner bio-one 
serological pipet, 25ml Greiner bio-one 
serological pipet, 50ml Greiner bio-one 
serological pipet, 2ml Falcon 
Combitips advanced®, 5ml Eppendorf 
Multipipet M4 Eppendorf 
Microscope: OPTECH® Optical Technology neoLab 
Thermomixer compact Eppendorf 
Centrifuge 5424 Eppendorf 
Centrifuge 5702 R Eppendorf 
HERAsafe, Scientific Biological Safety Cabinet ThermoFisher Scientific 
HERAcell Heraeus, CO2 Incubator ThermoFisher Scientific 
Centrifuge Tubes 15ml/50ml Sigma-Aldrich 
5.2. Preparation of McA-RH7777 for Tumor Implantation 
Cells were kept in culture as described above and last plated at least two days prior to preparation for 
implantation. On the day of implantation, cells were treated as follows: medium was aspirated and any dead 
cells washed off the culture dish with PBS. Cells were then trypsinized for 10 minutes in the incubator. All 
cells were pooled in 50ml centrifuge tubes in the appropriate cell culture medium. Cells were centrifuged at 
500g for 5 minutes and the supernatant discarded. Cells were washed in PBS to dispose of possible residues 
of trypsin and counted. The washed cells were centrifuged again, the supernatant discarded and the cells 
resuspended in their culture medium without supplements in a volume calculated to achieve a dilution of 
4x106 cells per 20µl. 
5.3. rVSV-NDV Production 
AGE1.CR.pIX cells were expanded on 20 cell culture dishes (150mm diameter) following normal 
maintenance protocol. At about 80% confluence, medium was changed to DMEM-F12 with 1% penicillin-
streptomycin and 1% L-glutamine. rVSV-NDV was added at an MOI of 0.001 and incubated for 
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approximately 48h. The optimal point in time of virus harvest is reached when the cells form large patches 
of syncytia, but before they completely detach from the dish. This time point is determined microscopically. 
To harvest the virus, the supernatant from culture dishes was collected in centrifuge tubes, and centrifuged 
at 300rcf for 10 minuntes to seperate cell debris, and the supernatant then transferred to ultracentrifuge tubes. 
0.001% Triton X was added to the cell layer in the dishes and incubated for 30min at 37°C. After incubation, 
cells were scraped off the dishes and collected in centrifuge tubes. The harvested cells were pooled with cells 
seperated from supernatant and vortexed for 1min, sonicated for 3min and centrifuged at 300rcf for 10min. 
After centrifugation the cell pellet was washed in 3ml PBS and centrifuged again. Supernatant from both 
steps was combined and transferred to ultracentrifuge tubes. Both types of supernatant in ultracentrifuge 
tubes (supernatant from culture dish and supernatant from washing the cell pellet) are centrifuged at 643rcf 
using a Beckman 70Ti rotor for one hour at 4°C. After ultracentrifugation, a small pellet appeared in each 
tube. Pellets from all the tubes were combined in 3ml PBS. Ultracentrifuge tubes were prepared with a sucrose 
gradient (7ml 60% sucrose on the bottom, 6ml 30% sucrose in middle layer, 3ml 10% sucrose on top). The 
combined pellets from ultracentrifugation were run over the sucrose gradient in an additional 
ultracentrifugation step at 643rcf for one hour at 4°C. Finally, the virus appears as a white band approximately 
at the transition of the bottom and middle layer of the sucrose gradient. Aliquots of the virus were frozen 
and stored at -80°C. 
5.4. Viral Titers 
Measurement of viral titers was accomplished by 50% Tissue culture infective dose (TCID50). 2x106 
AGE1.CR.pIX cells were plated on 96-well plates. A ten-fold serial dilution of virus containing material was 
pipetted in quadruplicates on the 96-well plate and incubated on the cells. Medium used for TCID50 was cell 
culture medium without fetal calf serum. Cells were observed for signs of CPE typical for the virus used and 
viral titers were calculated using the Reed-Muench method. 
5.5. Preparation of Tissue and Samples for TCID50 
Tissue samples were weighed and homogenized using a glass dounce homogenizer after resuspension in 10µl 
PBS per mg sample. Homogenized samples were then centrifuged at 100rcf for 5 minutes, and the 
supernatant was used for TCID50. Feces samples were additionally supplemented with 1% antibiotic-
antimycotic solution containing 10000 units/ml Penicillin, 10000µg/ml streptomycin and 25µg/ml 
amphotericin B. Urine samples were applied directly in TCID50 assays. Saliva was taken by wiping off mouse 
saliva from the oral mucosa with a moistened, cotton-tipped applicator. After taking the sample, liquid from 
the applicator was pressed into a 1.5ml Eppendorf-tube® equipped with 300µl PBS. After centrifugation at 
1rcf at 5 minutes to clear the supernatant from fiber of the cotton-tipped applicator, the supernatant was as 
well applied directly in TCID50 assays.  
5.6. McA-RH7777-T cell co-culture experiment 
To determine if virus-treated rats have stimulated antitumor T cell responses, a co-culture of the implanted 
tumor cells with T cells from rat blood, isolated from treated rats was performed. McA-RH7777 cells were 
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plated at a density of 1x105 cells per well in 12-well plates the day before the co-culture. Virus- and PBS-
treated rats were sacrificed and their blood was collected in EDTA-tubes. The fresh blood was then diluted 
1:2 in T cell medium and centrifuged over Biocoll separating solution, creating a Ficoll gradient. From this 
gradient, an aliquot of the plasma layer was aspirated and saved at -80°C for later use in neutralizing antibody 
assays. T cells were aspirated and pipetted into 2ml Eppendorf-tubes®. The pellet was washed twice in ice-
cold PBS and centrifuged for 5 minutes at 700rcf. After the second centrifugation step, the pellet was 
resuspended in 1ml T cell medium. Cells were counted and used for Morris-T cell-co-culture and flow 
cytometric analysis.  
After counting, the T cells were co-cultured together with the plated Morris cells in 12-well plates at effector-
target ratios of 1:2.5, 1:5 and 1:10 in duplicates. T cell medium was used for co-culture. 
After 48h, Morris cells were trypsinized and counted in a Neubauer chamber. 
5.7. Neutralizing Antibody Assay 
To compare the respective abilities of the virus to induce neutralizing antibody responses in their hosts, 
plasma samples from rats at different time-points post treatment were subjected to neutralizing antibody 
assays. Plasma samples were heat inactivated at 50°C and diluted 1:50 in DMEM-F12 supplemented with 1% 
Penicillin-Streptomycin and 1% L-glutamine. A 96-well plate was prepared with 100µl of the same medium 
in rows two to twelve. 200µl of the 1:50 plasma dilution was applied in quadruplicates to the first row. A 2-
fold serial dilution was then performed by transferring 100µl from the first row into the second and pipetting 
up and down. This procedure was repeated in each row to create a dilution series. The last 100µl in the last 
row were discarded. Additionally, 100µl of a 500 PFU/ml dilution of the virus against which the neutralizing 
antibodies should be directed was added to each well of the 96-well plate. This mixture was incubated for 90 
minutes and then pipetted onto the prepared AGE1.CR.pIX cells in a 96-well plate. The plates were evaluated 
microscopically after 48h. The neutralizing titer is determined as the highest plasma dilution in which at least 
50% of the wells are free from CPE. 
5.8. Flow Cytometry 
Dissociated tumor tissue and PBMCs from OV-treated rats were examined for Tcell markers (CD3, CD4, 
CD8 and CD25) by flow cytometry using antibodies conjugated to fluorochromes (Table 3). T-cells were 
prepared as described under section “McA-RH7777-T cell co-culture experiment”. The tumor tissue was 
minced and pressed through a cell strainer, and cells were resuspended in T cell medium and centrifuged 
25min at 100rcf. The pellet was washed twice in ice-cold PBS, and cells were counted. 1x106 cells of each 
sample (tumor and T cells) to prepare for flow cytometric analysis. For determination of cell viability, cells 
were washed in 1ml PBS and centrifuged for 10min at 300g. Cells were resuspended in 100µl PBS, and 1µl 
Viobility 405/520 Fixable Dye was added per sample to distinguish between living and dead cells by flow 
cytometry. The cells were then mixed well and incubated 15 minutes at room temperature for the dye to 
permeate the membrane of dead cells and bind intracellular proteins, which then fluoresce up to 50-fold 
brighter than living cells. Then 0.5µl CD25 monoclonal antibody (clone OX39) conjugated with Per-CP 
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eFluor 710 as a fluorochrome were added to each sample and incubated in the dark for 10 minutes. To 
eliminate unspecifically bound antibodies, samples were washed in FACS buffer, centrifuged at 0,4rcf for 
5minutes and then resuspended in 30µl FACS buffer. Following, 3µl of monoclonal CD4, CD8 and CD3 
antibody (conjugated to allophycocyanin [APC], phycoerythrin-cyanine dye [PE-Vio770] and phycoerythrin 
[PE], respectively) were added per sample. The samples were again mixed and incubated for 10 minutes at 4 
°C in the dark. Unspecifically bound antibodies were washed off in FACS buffer, centrifuged at 0,4rcf for 5 
minutes and the samples were resuspended in 200µl of 4% PFA to inactivate the virus. All samples were 
incubated 10 minutes on ice, washed in FACS buffer, centrifuged at 0,4rcf for 5min and resuspended in 200µl 
FACS buffer. All samples were analysed on a Gallios Flow Cytometer by Beckman Coulter. 
Table 3: Reagents Used for Sample Preparation for Flow Cytometric Analysis 
Reagent  Supplier Fluorochrome Excitation 
Laser 
Emission 
maximum 
Viobility 405/520 
Fixable Dye 
Miltenyi Biotec    
Anti-CD25 rat  
(OX39)  
ThermoFisher Per-CP eFluor710 488nm 710nm 
Anti-CD4 rat APC Miltenyi Biotec Allophycocyanin 670nm 680nm 
Anti-CD8 rat PE-
Vio770 
Miltenyi Biotec Phycoerythrin-cyanine 488nm 780nm 
Anti-CD3 rat PE Miltenyi Biotec Phycoerythrin 488nm 630nm 
5.9. Virulence in Embryonated SPF Chicken Eggs 
The pathogenic potential of VSV-NDV in birds was investigated by conduction of experiments to study the 
mean death time in 10-day old, embryonated and specific pathogen free chicken eggs. 40 Eggs were delivered 
from Charles River at a temperature of 36°C. The eggs were inoculated on the same day with either 10 PFU, 
100 PFU, 1000 PFU or 10000PFU of VSV-NDV or NDV-GFP as a control. Eggs were candled using a 
torch light and the embryo averted side was marked. To inoculate the virus, the eggshell was first punctured 
at the top with a 27G-needle to release pressure for the virus injection. Afterwards, the virus was injected in 
a 100µl volume using a 1ml syringe and a 30G-needle on the marked side of the egg into the allantoic cavity. 
Punction sites were closed with candle wax and the eggs observed by candling twice daily for 90 hours and 
again after 7 days to determine the mean death time and minimum lethal dose. 
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Figure 14: Procedure of egg inoculation 
100µl of either rNDV-GFP or rVSV-NDV diluted according to the experimental groups was injected into the allantoic 
sack of embryonated, specific pathogen free chicken eggs using a 30G-needle. 
5.10. Animal Models and Experimental Designs 
All animals were kept in small groups under specific pathogen free conditions in IVC cages with controlled 
air and temperature conditions and humidity. Food and water were provided ad libitum. All experiments were 
conducted in agreement with §8 Animal Welfare Act (“Tierschutzgesetz”) and approved by the government 
of Upper Bavaria (“Regierung von Oberbayern”) under reference numbers 55.2-1-54-2532-43-13 and 55.2-
1-54-2532-16-15.  
For the viral safety studies, seven-week old NOD-SCID (non-obese diabetic severe combined 
immunodeficiency) mice were used to induce viral toxicity at lower virus titers. These mice provide a broad 
immune deficiency through impaired B and T cell function on the background of deficient Natural Killer cell 
function.  
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Figure 15: Setup of the viral safety study 
7-week-old NOD-SCID mice were injected with 1x106 TCID50 of either rVSV-GFP or rVSV-NDV and observed 
until they reached endpoint criteria, determined by daily control of body weight and general condition. Blood samples 
were taken on days 1, 7 and the day of sacrification and used to measure BUN, CREA and GPT. 
Survival experiments were performed in immune competent animal models. A mouse survival study was 
conducted in seven to ten week old AST-LTAg (albumin-floxstop-Tag, large T-Antigen) mice. This animal 
model allows inducible growth of spontaneously developed HCC, which mirrors the clinical conditions much 
better than an implanted tumor-model. The genome of these mice contains a Cre/loxP system on a 
C57BL/6J (often referred to as Black-/6) background. A lox/P-flanked stop cassette and the Simianvirus 40 
(SV40) large tumor-antigen (LTag), a well-known oncogene in rodents, are integrated into the genome directly 
following the liver specific albumin promoter. These mice, when injected with an adenovirus expressing the 
Cre-recombinase develop spontaneous HCC. The Cre-recombinase results in cleavage of the lox/P site and 
cuts out the stop cassette 106. This leads to expression of the L-Tag in a liver specific context and thus to 
development of HCC within 7-10 weeks after tail vein injection of 2.5x108 PFU of rAd-Cre. 
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Figure 16: Setup of the HCC tumor model in AST-mice 
The cre/loxP system induces expression of the oncogene in a liver specific context in AST-mice after injection of the 
Cre-recombinase via injection of an adenovirus carrying the recombinase. Tumors develop over time in a 4-9 week 
period. Starting in week 4 tumors were detected using MR Imaging. Mice that reached inclusion criteria were treated for 
survival studies according to their experimental group and euthanized when they reached endpoint criteria. 
Additional survival experiments and studies on viral kinetics and distribution were conducted in seven to 
twelve week-old Buffalo rats. The rats were bred and delivered from Charles River (Calco). Buffalo rats are 
the syngeneic rat strain from which Morris Hepatoma 7777 cell line was derived, and therefore are the only 
immune-competent model in which these cells will grow.  
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Figure 17: Time line of rat survival (A, B) and kinetics (C) experiments 
Tumors were implanted in 7-12 week old Buffalo rats. 11 days after tumors were implanted a second laparotomy was 
performed and virus or PBS was injected according to the treatment group. A Virus or PBS was injected via the hepatic 
artery. The rats were monitored regularly and body weight and general condition were determined to evaluate if animals 
reached endpoint criteria in the survival study. B Virus or PBS was injected intratumorally. The rats were monitored 
regularly and body weight and general condition were determined to evaluate if animals reached endpoint criteria in the 
survival study. C Virus or PBS was injected intratumorally. The rats were sacrificed after 1, 4 or 7 days and blood and 
tissue was harvested for viral kinetics studies. 
 
 
42 
 
Figure 18: Setup of the experiment on viral shedding 
AST-mice were injected with 1x107 TCID50 of either rVSV-NDV or rVSV-GFP via tail vein injection. Samples of saliva, 
urine and feces were collected within the first three days after injection and TCID50 was performed to determine viral 
titers in secretions of injected mice. 
5.11. Administration of Viral Vectors in the Mouse Model 
Mice in the appropriate age range were fixated for a short time span in a tail-first restrainer. An infrared heat 
lamp was directed to the tail of the mouse in a distance of 30cm to dilate the veins. The tail was wiped with 
80% ethanol. When the lateral tail veins were clearly visible, a 1ml syringe containing the appropriate virus at 
the appropriate dose in a volume of 100µl volume was used to inject the virus, in the absence of air bubbles 
into the vein, using a 30 Gauge needle.  For survival studies, a dose of 1x107 TCID50/ mouse was applied. 
After the application, eventual-bleeding was stopped by the application of gentle pressure with a cellulose 
swab on the puncture site. Before the injection, the viruses were kept on ice at all times.  
5.12. Magnetic Resonance Imaging 
For magnetic resonance imaging (MR imaging, MRI) all mice were anaesthetized using Isoflurane as 
inhalation anaesthesia. Induction was reached with 4% Isoflurane in 100% oxygen. Anaesthesia was 
maintained with 2.5% Isoflurane in 100% oxygen (airflow: 1l/min). Anaesthetized mice were placed in a 
dStream wrist coil and imaged with “Ingenia 3.0T MR-System” by Philips. The sequence used was fat 
saturated T2-weighted RARE (rapid acquisition with relaxation enhancement) imaging (3403.35/100.517 
[repetition time msec/echo time msec]). Ointment was applied to the eyes of all mice during anaesthesia, and 
to maintain body temperature, the tail was placed on a glove filled with physiologically warm water during 
imaging. 
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5.13. Preparation for Surgery, Pain Medication and Euthanasia 
After at least one week of quarantine, seven to twelve-week old Buffalo rats were assigned for experimental 
use. All rats were injected subcutaneously with 0.05mg/kg Buprenorphin 20min prior to surgery. The rats 
were then introduced into inhalation anaesthesia via a flooded chamber with 4% Isoflurane in 100% oxygen 
(airflow: 2l/min). For maintenance, the rats were placed in an inhalation mask and provided with 2% 
Isoflurane in 100% oxygen (airflow: 2l/min). To prepare the rats for surgery, they were placed on a heat mat, 
Bepanthen® eye-cream was applied on all rats under anaesthesia. The operation site was shaved and 
disinfected with 80% ethanol and Braunol® was applied as an antiseptic. 
After surgery, all rats received subcutaneous injection of 4ml 0,9% saline solution, Metamizol 50mg/kg orally 
and subcutaneous injection of 0.05mg/kg Buprenorphin every 8 hours. The period of analgesia was 
dependent on the performed surgery. For tumor implantation and intratumoral injection, Buprenorphin was 
applied over a period of 36 hours after surgery. After hepatic artery injection, Buprenorphin was applied for 
72 hours, as this surgery is much more invasive. The rats were weighed and scored frequently after surgery. 
Animals in survival studies were euthanized by injection of 200-400mg/kg Narcoren® under inhalation 
anaesthesia when humane endpoints were reached. 
5.13.1. Tumor Implantation 
The rats were prepared for surgery as described above. Laparotomy was performed by an approximately 3cm 
long incision of skin and muscle layer from the xiphoid process down. The skin and muscles were hold in 
place by a wound retractor. A gauze swab moistened with physiological saline solution was placed at the 
lower incision site and the left lateral hepatic lobe was lifted out gently on the swab using moistened cotton-
tipped applicators. Using a dissection microscope, 4x106 cells in a 20µl volume were injected through a 30 
Gauge needle, attached to a Hamilton syringe into the liver lobe. The needle was inserted until the tip was 
visible directly under the liver capsule, then the cells were injected creating a visible bubble under the liver 
surface. A long injection canal was created in order to reduce tumor cell leakage and to prevent destruction 
of the tumor cells during the subsequent cauterization to close the injection site. After reassuring that no 
bleedings could be observed, the liver lobe was placed back into the abdomen. The muscle and skin layer 
were sutured separately with 4-0 PROLENE® suture material. Tumors grew for eleven days until either 
hepatic artery injection (survival) or intratumorale injection (viral kinetics) of therapy was performed. 
 
Figure 19: Procedure of intrahepatic tumor implantation 
20µl of the Morris Hepatoma cell line McA-RH7777 were injected into the liver directly under the capsule, 
creating a long and curved needle track to circumvent cells from leaking out of the injection site. Additionally 
the needle track was closed by cauterizing the tissue at the entrance of the needle track. 
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5.13.2. Hepatic Artery Injection 
At day eleven after tumor implantation, a second laparotomy was performed to inject the virus into the 
hepatic artery. Skin and muscle were incised approximately 5cm from the xiphoid down in caudal direction. 
The incision was kept wide open using a wound retractor. Gauze-swabs were moistened with physiological 
saline solution and placed on both ends, in a cranial and caudal direction, of the incision. With moistened, 
cotton-tipped applicators, the intestines were placed on the lower gauze-swab and covered. The gauze swab 
was kept moist at all times. Under magnification by a dissection microscope, the left lateral lobe, the anterior 
caudate lobe and the posterior caudate lobe were extricated from the liver capsule, a filamentous membrane 
surrounding each lobe, using delicate forceps. After extraction from the capsule, the lobes were wrapped in 
the upper gauze-swab to keep them moist and in place, out of the surgery area. With these preparations, the 
junction of the common hepatic artery and gastroduodenal artery to the proper hepatic artery became visible 
and was dissected from surrounding fat and ligaments. The gastroduodenal artery was then closed as far 
caudal as possible with a ligature using a 7-0 PROLENE®. The common hepatic artery was clamped using 
an artery clamp for at most 5min. In these 5min the virus was injected into the gastroduodenal artery, cranial 
of the ligature to create a flow into the proper hepatic artery and the thus the tumor providing vessels. 
The virus was prepared in 1ml syringes with a concentration and volume of 1x107 in 1ml PBS. Viruses were 
kept on ice at all times before injection. 
 
Figure 20: Surgery procedure of the hepatic artery injection 
The rats received a second laparotomy 11 days after the tumor implantation. The liver lobes were decapsulated and 
flipped aside to achieve access to the blood vessels underneath. Using a microscope the branching of gastroduodenal 
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artery, common hepatic artery and proper hepatic artery was dissected. A A clamp positioned on the common hepatic 
artery and a ligature on the gastroduodenal artery prevents back flow of the injected virus. The flow of injected virus 
into the tumor is marked by a green arrow. B A second ligature inclosing the injection site on the gastroduodenal artery 
prevents bleeding after the clamp on the common hepatic artery is removed and the blood flow to the liver via the 
proper hepatic artery is restored. The blood flow after a successful surgery is indicated by a red arrow. 
After the virus was carefully injected through a 30 Gauge needle, bleeding is prevented by a second ligature 
cranial to the puncture site and directly before the junction of the gastroduodenal artery and the common 
hepatic artery with a 7-0 PROLENE®. When the second ligature was safely in place the blood flow was re-
established by removing the artery clamp from the common hepatic artery. When the absence of bleeding is 
confirmed, the liver was placed back in physiological order into the abdomen. The intestines were placed 
back with special attention to the correct orientation of the caecum. The muscle and skin layer were closed 
in separate layers with continuous suture using a 4-0 PROLENE®. 
5.13.3. Intra-tumoral Injection 
On day eleven after tumor implantation, a second laparotomy was performed to inject the virus directly into 
the tumor nodule. Rats were prepared for surgery as described, and again the skin and muscle layer were 
opened with an incision 3cm down from the xiphoid. The liver was lifted out on a moistened gauze swab 
using moistened cotton tipped applicators to expose the tumor nodule on the liver surface.  
The virus was prepared in 1ml syringes in a concentration and volume of 1x107 TCID50 in 200µl in PBS. 
Viruses were kept on ice at all times before injection. 
The virus dilution was injected into the tumor through a 30G needle directly into the centre of the nodule. 
After injection, the liver was placed back into the abdomen and the muscle and skin layers were closed with 
a continuous suture using a 4-0 PROLENE®. 
Table 4: Surgery Instruments 
Surgical instruments  Surgery 
FST: Surgical scissors, sharp/blunt, straight, 17cm Tumor implantation, Hepatic Artery injection, 
Intratumorale injection 
FST: Alm Retractor, curved, 7cm Tumor implantation, Hepatic Artery injection, 
Intratumorale injection 
Feather: Disposable Scalpel No. 22 Tumor implantation, Hepatic Artery injection, 
Intratumorale injection 
Ethicon: PROLENE 4-0 Tumor implantation, Hepatic Artery injection, 
Intratumorale injection 
Sigma-Aldrich: Hamilton® Syringe 50µl Tumor implantation 
FST: Bovio Cauterizer Kit Tumor implantation 
FST: Vannas Spring Scissors, 2mm blades Hepatic Artery injection 
FST: Delicate Forceps 0.4mm, Tip Angled Hepatic Artery injection 
FST: Castroviejo Needle Holder, 9cm Hepatic Artery injection 
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Ethicon: PROLENE 7-0 Hepatic Artery injection 
FST: Schwartz Micro Serrefine, 26mm Hepatic Artery injection 
FST: Micro-Serrefine Clip Applying Forceps Hepatic Artery injection 
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6. Results 
6.1. Safety of the viral vector 
Viral safety was investigated by tail vein injection of 1x106 TCID50 of either rVSV or rVSV-NDV, with three 
NOD-SCID mice randomly assigned per group. The mice were weighed daily and blood samples were taken 
on day 1, day 7 and the day of sacrifice. All VSV treated mice showed illness with neurological symptoms e.g. 
wandering in circles or paralysis, which led to sacrifice, at day 12, 13 and 14 after injection. rVSV-NDV 
treated mice survived three weeks without showing any illness and were sacrificed 21 days after injection 
(Figure 21). Weight measurements indicated a significant(*) weight loss of VSV treated mice accompanying 
the neurological symptoms compared to rVSV-NDV treated mice on their day of euthanization (Figure 25). 
The blood samples were centrifuged and serum was harvested and diluted 1:10 for photometric measurement 
of blood urea nitrogen (BUN), creatinine (CREA), and Glutamtate-Pyruvate-Transalaminase (GPT). BUN 
and CREA stayed within physiological range for this mouse strain (Figure 22). GPT values were strayed 
within a wide range, both lower and higher than physiological reference indicates (Figure 22). Blood samples 
were as well tested on viral titers by TCID50. There were average titers of 1.8x103 TCID50/ml VSV in blood 
on day 1 and 7 after treatment and one mouse had a titer of 5.62 TCID50/ml on the day of sacrifice. No titer 
of VSV-NDV was measurable at these points in time (Figure 24). On day of sacrification, liver and brain 
were harvested and examined on viral titers by TCID50. There are average titers of 5.62x102 TCID50/ml VSV-
GFP in the brain of VSV-GFP treated mice. Both treatment groups showed titers of 3.3x101 TCID50/mg for 
VSV-GFP and 2.2x101 TCID50/mg for VSV-NDV in liver tissue (Figure 23). 
 
 
Figure 21: Survival of virus-treated NOD-SCID mice after systemic injection of 1x106 TCID50 
rVSV-NDV and rVSV were injected at doses of 1x106 TCID50 via tail vein into NOD-SCID mice. Mice were 
monitored daily and euthanized at humane endpoints when signs of severe toxicity were observed. VSV-injected mice 
were euthanized on days 12, 13 and 14 after treatment, due to extreme weight loss and/or neurological symptoms, 
such as wandering in circles and paralysis. VSV-NDV-treated mice did not show any signs of toxicity over the course 
of the experiment, and were sacrificed on day 21 after injection for analysis of tissue. 
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Figure 22: Blood Urea Nitrogen, Creatinine and Glutamate-Pyruvate Transalaminase of virus treated NOD-
SCID mice after systemic injection of 1x106 TCID50 
On day of sacrifice blood samples were taken and Serum was diluted 1:10 and measured via photometry by the blood 
chemistry lab of “Klinikum rechts der Isar”.Plasma was used to determine A blood urea nitrogen (BUN), B creatinine 
(CREA) and C Glutamate-Pyruvate-Transalaminase (GPT)..All measured values for BUN and CREA are within 
reference range, indicating normal kidney function, regardless of virus therapy. 
 
 
Figure 23: Viral titer in organs of virus treated NOD-SCID mice on day of euthanasia 
After sacrification brain and liver were harvested and analysed by TCID50. VSV-treated mice showed titers of around 
5.62x102 TCID50/mg in the brain, whereas VSV-NDV treated mice had no measurable viral titer. In both treatment 
groups, low viral titers could be detected in the liver. 
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Figure 24: Viral titer from serum of virus-treated NOD-SCID mice after systemic injection of 1x106 TCID50 
Blood samples were taken on day 1 and 7 and on day of sacrifice. Viral titers in serum were measured by TCID50. 
There was no measurable titer of rVSV-NDV in serum samples, whereas VSV-treated mice showed average titers of 
1.8x103 TCID50/ml on day one and seven and one of the mice a low titer of 5.62 TCID50/ml on day of 13 after 
injection, which is not depicted in the figure. 
 
Figure 25: Weight of virus-treated NOD-SCID mice after systemic injection of 1x106 TCID50 of rVSV or rVSV-
NDV  
Over the course of the toxicity study, mice were weighed daily. Weights were stable until day eleven, at which time 
weights dropped in the VSV treated group. rVSV-NDV treated mice showed stable body weight throughout the 
course of the experiment. 
6.2. Virus Shedding 
Samples of feces, urine and saliva were collected in the first three days after viral treatment. Saliva was taken 
by wiping off mouse saliva from the oral mucosa with a moistened, cotton-tipped applicator. After taking the 
sample, liquid from the applicator was pressed into a 1.5ml Eppendorf-tube® equipped with 300µl PBS. 
Urine of fixated mice was collected from spontaneous emiction into a 1.5ml Eppendorf-tube®. 
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Samples were prepared as described in “Material and Methods” and TCID50 was performed, to determine 
whether infectious virus could be recovered from the shed material. Evaluation of TCID50 showed no viral 
titer at any point in time neither in VSV-GFP nor in VSV-NDV treated mice. 
6.3. Virulence in Embryonated Chicken Eggs 
To investigate the pathogenic potential of VSV-NDV in birds, a virulence test was performed. 10-day old 
embryonated chicken eggs with SOPF quality were inoculated with either rNDV-GFP or rVSV-NDV in one 
of the four dose levels. Mean death time was investigated by candling the eggs twice daily over the course of 
90 hours and again seven days after inoculation. The minimum lethal dose is the virus dose that kills all 
embryos in its group and the mean death time is the mean time in which all embryos in a group die. No 
minimum lethal dose was detectable for VSV-NDV. None of the tested doses of VSV-NDV killed all the 
embryos in a group, so there was no minimum lethal dose or mean death time detectable. NDV showed a 
minimum lethal dose of 100PFU and a mean death time of 84 hours (Table 5), corresponding to a mesogenic 
strain, which is consistent to previous findings in the research group. 
Table 5: Mean Death Time and Minimum Lethal Dose of NDV-GFP and VSV-NDV in Embryonated Chicken 
Eggs 
 NDV-GFP VSV-NDV 
Virus Dose Mean Death Time Minimum Lethal 
Dose 
Mean Death Time Minimum 
Lethal Dose 
10 PFU n=5 -  n=5 - not applicable 
100PFU n=4 84 hours 100PFU n=4 - not applicable 
1000 PFU n=5 75.6 hours  n=5 - not applicable 
10.000 PFU n=4 65 hours  n=5 - not applicable 
6.4. Survival Experiment 
A survival experiment was conducted in AST mice and Buffalo rats. In Buffalo rats two models of OV 
treatment, intraarterial injection and intratumoral injection, were compared. Tumor growth in AST mice was 
induced by systemic Ad.Cre injection, leading to a spontaneous growth of multifocal tumors. To underline 
the translational aspect of the AST mouse model, data supporting this aspect will be given in the following 
section.  
AST-LTAg mice developed HCC spontaneously after injection of Cre-recombinase adenovirus. To 
determine a start point for viral treatment of HCC-bearing mice, in context of the survival study, they were 
imaged using magnetic resonance tomography from four weeks after injection onwards. Treatment was 
started once a mouse reached either an intrahepatic tumor size of 0.5cm or at least three tumors with an 
additive diameter of 0.5cm. Most mice were ready for treatment between weeks seven and eight after injection 
of Cre-recombinase adenovirus (Figure 26), but in general the detection of tumors within criteria for 
treatment start was spread between four and twelve weeks . From this observation, a classification into fast 
  51 
growing tumors with a tumor growth within eight weeks and slow growing tumors with a tumor growth from 
nine weeks onwards seemed useful. After Ad.Cre injection, 100% of male mice developed tumors fast within 
the first eight weeks. The Female population is divided almost in half between slow and fast growing tumors, 
which means significantly (***) less fast growing tumors than observed in the male population. (Figure 26). 
More over, fast growing tumors tended to be divided into multiple origins of tumor growth with smaller 
sizes. Slow growing tumors were often derived from two origins with bigger diameters (Figure 26). A one-
tailed Mann Whitney test on statistical significance showed that female mice grow tumors significantly later 
than male mice (average start of tumor growth 61.33 days after treatment to 47.72 days after treatment, 
respectively). 
 
Figure 26: Specifications on tumor development in the AST mouse model 
For a survival study in HCC-bearing mice with OV treatment, spontaneous tumor growth in AST mice was produced 
by injection of Ad.Cre. A The figure shows the distribution of tumor development over time in AST-LTAg mice. 
Depicted is the day of first tumor detection after Ad.Cre injection in 30 Mice (100%) using MR imaging. Tumors were 
identified as such with a minimum diameter of 0.2cm. B The figure shows the division of slow (within nine weeks) 
and fast growing (from nine weeks onwards) tumors in male and female mice. In total, 16 males and 14 females were 
injected with Cre-recombinase adenovirus. 100% of male mice developed fast growing tumors, whereas 53% of 
female mice developed slow growing tumors and 46% fast growing tumors. C When the start point for viral treatment 
was set by MR imaging, the number of tumors was counted. Depicted is the relation of tumor quantity to slow and 
fast growing tumors (n=7 and n=19, respectively). On average, two tumors were detected when tumors were slow 
growing, while five were detected when fast growing tumors reached inclusion criteria for treatment start. Means+/- 
standard deviation are shown. D When the start point for viral treatment was set by MR imaging, sizes of tumors were 
measured. Depicted is the relation of tumor size to slow and fast growing tumors (n=7 and n=19, respectively). The 
average size of a slow growing tumor at treatment start was 0,77cm. For fast growing tumors the average size was 
0,4cm. Means+/- standard deviation are shown. 
The rats were implanted intrahepatic with a single tumor node. When tumors reached inclusion criteria for 
treatment start, a viral vector or PBS as control was injected, systemically in the mouse model and via hepatic 
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artery injection or intratumoral injection in the rat model. The survival experiment in twelve AST-LTAg mice 
with the inducible HCC tumor model showed prolonged survival of the five rVSV-NDV treated mice 
compared to the four VSV-GFP and significantly(**) prolonged survival compared to the five PBS treated 
mice (Figure 27). Whereas most of the rVSV-GFP and PBS treated mice were euthanized between days 14 
and 21, the rVSV-NDV treated mice were euthanized on day 33 and 35. Survival experiments in Buffalo rats 
with a single implanted HCC node and treatment via injection of the oncolytic viral vector or PBS into the 
proper hepatic artery resulted in euthanization ranging between day 10 and 46, evenly distributed between all 
groups (Figure 28). Whereas the day of euthanization for PBS-treated rats in the interquartile range varied in 
a wide span between days 18 and 38, these points in time lay in a more defined area between days 20 to 30 
for virus-treated rats in the interquartile range (Figure 28). Survival experiments in Buffalo rats treated via the 
intratumoral application route resulted in significantly(*) prolonged survival of rVSV-NDV treated rats 
compared to the PBS control.  
 
Figure 27: Survival of male, HCC-bearing AST-LTAg mice after injection of 1x107 TCID50 
Male, HCC-bearing AST-LTAg mice were injected twice in a seven-day span with 107TCID50 of either rVSV-GFP or 
rVSV-NDV via tail vein injection for treatment. As a control mice were injected with an equal volume of PBS. Criteria 
for treatment start included a minimum tumor size of 0.5cm (single node or additive, with one node at least 0.2cm) 
and a maximum of 10 tumor nodes. Following the treatment mice were monitored regularly and euthanized when they 
reached human endpoints. 
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Figure 28: Survival of male, HCC-bearing Buffalo rats after hepatic artery injection of 1x107 TCID50 
Male Buffalo rats were surgically implanted with intrahepatic HCC in a single node. Eleven days after implantation, 
tumors reached a size of approximately 0.5cm. At this point in time, in a second surgery, the virus or control buffer 
was injected for treatment A via the proper hepatic artery or C via intratumoral injection. The rats were monitored 
closely after treatment and euthanized when humane endpoints were reached. A OV-treatment of rats did not result in 
prolonged survival compared to the PBS control. B Depicted is the number of survived days of HCC-bearing Buffalo 
rats after intraarterial treatment. C OV-treatment of rats resulted in significantly(*) prolonged survival compared to 
the PBS control. 
 
6.5. Viral Kinetics Experiment 
For experiments on viral kinetics, Buffalo rats were implanted with a single, intrahepatic HCC node in the 
same manner as for the survival experiments. Treatment in this experiment set-up, was performed by intra-
tumoral injection of the viral vector or PBS eleven days after tumor implantation. The rats were euthanized 
on either day one or seven after treatment and samples of blood, liver, tumor and brain were taken to perform 
experiments on viral kinetics. The different treatment groups were investigated with respect to viral titer in 
tumor, liver, and brain, the development of neutralizing antibodies, and the development of tumor-specific 
T cells by co-culture of the cell line used for tumor implantation and PBMCs derived from blood from the 
treated rats. It is important to note that these data are only preliminary, as the treatment group size was only 
one or two rats on day one, and on day seven, the control group consisted only of a single PBS-treated rat. 
Therefore, no conclusions can be drawn from these experiments. 
Viral titers in organs were seen on day one in tumor tissue only for the rVSV-GFP and rVSV-NDV treated 
group with an average titer of 1.58x105 TCID50/mg and 1,09x102 TCID50/mg, respectively (Figure 29). 
Although the differences between the values varied a lot, viral titers were detectable in all rVSV-GFP and 
rVSV-NDV treated rats. On day seven, viral infection shifted in the VSV-GFP treated group to brain and 
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liver tissue with an average titer of 4.45x104 TCID50/mg and 7.9x101 TCID50/mg, respectively (Figure 29). 
In tumor tissue a viral titer of 1.58x101 TCID50/mg was measured for the VSV-GFP treated group. On day 
seven, no viral titer of NDV-GFP or VSV-NDV was measurable in any of the collected tissues. 
Neutralizing antibodies were detected in the NDV-GFP treated rat as early as on day one after treatment 
with a neutralizing titer of 1:100 and on day seven after treatment the titer decreased to 1:50. Neutralizing 
titers for rVSV-GFP were detected on day seven after treatment with an average neutralizing titer of 1:25. At 
the measured time points no titer of neutralizing antibodies was found in rVSV-NDV treated rats (Figure 
30). 
Results of the Morris cell-PBMC co-culture showed that PBMCs isolated on day one after treatment resulted 
in a wide range of viable target cells and there is no correlation between percentage of viable cells and 
treatment group or effector-target ratio (Figure 31). On day seven, the Morris-PBMC co-culture resulted in 
consistent numbers of viable cells in the PBS treated group for each effector-target ratio. For the rVSV-NDV 
treated group, the percentage of viable cells increased with decreasing effector-target ratios. For rVSV-GFP, 
there is no change in the number of viable cells, regardless of the effector-target ratio (Figure 31). It is not 
possible to make a comparison between target cell viability after co-culture with PBMCs derived from virus-
treated rats and PBS-treated rats, since there was only a single rat in the PBS-treatment group. 
Flow cytometric analysis of CD3+, CD4+, CD8+ and CD25+ T cells on day one after treatment showed a 
trend indicating an increase of all subpopulations in rVSV-NDV treated rats compared to VSV-GFP or PBS 
(Figure 32). On day seven after treatment, there is no significant increase in activated T cell subpopulations 
of rVSV-NDV treated rats compared to rVSV-GFP or PBS. rNDV-GFP treated rats showed a trend toward 
increased activation of CD4+ T cells compared to the other groups (Figure 33). Analysis of tumor infiltrating 
T cells indicate an increase in CD8+T cells of all virus treated groups compared to PBS (Figure 33). However, 
it must be noted that these are only preliminary data and some treatment groups contain only one or two 
treated rats. Therefore, no definitive conclusion can be drawn. 
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Figure 29: Viral titer in organs of virus-treated, HCC-bearing Buffalo rats 
Buffalo rats were implanted with a single, intrahepatic HCC node and treated eleven days after implantation via intra-
tumoral injection of either rVSV-GFP, rNDV-GFP (not shown), rVSV-NDV or PBS as control. On A day 1 or B day 
7 after treatment the rats were euthanized and samples of liver tissue, tumor and brain were collected. Depicted is the 
viral titer in TCID50/mg of tissue on day one after treatment. Means + standard deviation are shown. 
 
 
Figure 30: Neutralizing antibody titer from serum of virus-treated, HCC-bearing Buffalo rats 
Buffalo rats were implanted with single, intrahepatic HCC nodules and treated eleven days after implantation via intra-
tumoral injection of either rVSV-GFP, rNDV-GFP, rVSV-NDV or PBS as control. On day 1 or 7 after treatment the 
rats were euthanized and samples of blood were collected. Blood samples were separated into plasma and PBMCs 
using a Ficoll- gradient. Depicted are the results of a neutralizing antibody assay from plasma samples of rVSV-GFP 
and rNDV-GFP treated rats. Means + standard deviation are shown. 
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Figure 31: Co-culture of McA-RH7777 cells with PBMCs from HCC-bearing Buffalo rats  
Buffalo rats were implanted with single, intrahepatic HCC nodules and treated eleven days after implantation via intra-
tumoral injection of either rVSV-GFP, rNDV-GFP, rVSV-NDV or PBS as control. On A day 1 or B day 7 after 
treatment the rats were euthanized, and blood samples were separated into plasma and PBMCs using a Ficoll- 
gradient. Depicted are the results of a Morris cell-PBMC co-culture in three different effector-target ratios (1:2.5, 1:5 
and 1:10). Means + standard deviation are shown. 
 
Figure 32: Flow cytometric analysis from blood of PBS and virus-treated, HCC-bearing Buffalo rats on day 1 
and 7 after treatment 
Buffalo rats were implanted with single, intrahepatic HCC nodules and treated eleven days after implantation via intra-
tumoral injection of either rVSV-GFP, rVSV-NDV or PBS as control. On day one or seven after treatment the rats 
were euthanized and blood was collected. PBMCs were separated from blood samples and analysed by flow 
cytometric analysis on stimulation of CD3+, CD4+, D8+ and CD25+ T cells. Means + standard deviation are shown. 
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Figure 33: Flow cytometric analysis from tumor cells of PBS and virus-treated rats on day 7 after treatment 
Buffalo rats were implanted with single, intrahepatic HCC nodules and treated eleven days after implantation via intra-
tumoral injection of either rVSV-GFP, rVSV-NDV or PBS as control. On day one or seven after treatment the rats 
were euthanized and blood was collected. PBMCs were separated from blood samples and analysed by flow 
cytometric analysis on stimulation of CD3+, CD4+, D8+ and CD25+ T cells. Means + standard deviation are shown. 
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7. Statistical Analysis 
All data was depicted and analyzed with GraphPad Prism version 7 (GraphPad software, La Jolla California, 
USA). A confidence interval of 95% was applied in all tests, therefore p-values less than 0.05 were considered 
to be statistically significant. In all tests a two-sided level of significance was used. Statistical significance is 
shown in one to three asterisks, one asterisk (*) means p-values are less than 0.05, two asterisks (**) mean p-
values are less than 0.01 or three asterisks (***) mean p-values are less than 0.001. 
Survival data are in general depicted in Kaplan-Meier survival curves and were analyzed using the log-rank 
test.  
Survival data of rats treated with the OV via intra-arterial injection were additionally plotted as Whisker-plot. 
As there are more than three unpaired groups and Gaussian distribution can be expected, the applied test 
method to determine if variances differ significantly between the groups is one-way ANOVA. 
Levels of viral titer in any given tissue were depicted in scatter plots and analyzed using Mann-Whitney-U 
test. Compared were two independent groups with assumed arbitrary distribution. 
The differences in body weight of NOD-SCID mice on their day of death for the viral safety study were 
depicted as line graph. The compared values are independent values with parametric distribution, therefore 
t-test for independent samples was chosen as statistical test. 
To analyze statistical significance of the difference in start of tumor growth after Ad.Cre-induction in slow 
growing and fast growing tumors, depicted as bar charts, Mann-Whitney-U test was used as 2 independent 
groups with assumed arbitrary distribution of the test results were analyzed.  
The t-test for independent samples was used to analyze statistical significance of the difference of tumor seize 
at treatment start in the inducible HCC model, viral titer of organs between treatment groups and immune 
stimulation between the treatment groups. This test method was chosen as comparison was drawn between 
two independent and unpaired treatment groups and parametric distribution of the results was assumed. The 
results are depicted as bar charts. 
Figure # Experiment Comparison Significance P-Value Test Method 
21 survival in 
safety study 
rVSV-GFP vs. 
rVSV-NDV 
* 0.0246 logrank test  
23 viral titer in 
organs in  
Brain: rVSV-GFP 
vs. rVSV-NDV 
ns 0.0636 Mann-Whitney U test 
23 viral titer in 
organs in  
Liver: rVSV-GFP 
vs rVSV-NDV 
ns 1000 Mann-Whitney U test 
24 serum titer in 
safety study 
Day 1: rVSV-GFP 
vs. rVSV-NDV 
ns 0.1967 Mann-Whitney U test 
60 
24 serum titer in 
safety study 
Day 7: rVSV-GFP 
vs. rVSV-NDV 
ns 0.1967 Mann-Whitney U test 
24 serum titer in 
safety study 
Day 13: rVSV-
GFP vs. rVSV-
NDV 
ns 0.5050 Mann-Whitney U test 
25 weight 
development in 
safety study 
Date of death: 
rVSV-GFP vs. 
rVSV-NDV  
* 0.0146 unpaired t-test 
26 HCC-model 
 
slow growing vs. 
fast growing in 
male and female 
mice 
*** 0.0005 Fisher’s exact test 
26 HCC-model 
# of tumors at 
treatment start 
slow growing vs. 
fast growing 
tumors 
ns 0.2718 Mann-Whitney U test 
26 HCC-model 
seize of tumors 
at treatment 
start 
slow growing 
tumors vs. fast 
growing tumors 
ns 0.1298 t-test for independent 
samples 
27 survival in AST 
mice 
PBS vs. rVSV-
NDV 
** 0.0034 logrank test 
27 survival in AST 
mice 
rVSV-GFP vs. 
rVSV-NDV 
ns 0.0625 logrank test 
28 survival in rats 
i.a. injection 
PBS vs. rNDV vs. 
rVSV-GFP vs. 
rVSV-NDV 
ns 0.8413 logrank test 
28 survived days 
i.a injection 
PBS vs. rNDV vs. 
rVSV-GFP vs. 
rVSV-NDV 
ns 0.8717 
0.3615 
one-way ANOVA: means 
one-way ANOVA: variances 
28 survival in rats 
i.t. injection 
PBS vs. rVSV-
NDV 
* 0.0246 logrank test 
28 survival in rats 
i.t. injection 
rVSV-GFP vs. 
rVSV-NDV 
ns 0.2689 logrank test 
29 TCID50 of 
organs in 
kinetics study 
day 1 tumor: 
rVSV-GFP vs. 
rVSV-NDV 
ns 0.2721 t-test for independent 
samples 
29 TCID50 of 
organs in 
kinetics study 
rVSV-GFP brain: 
day 1 vs. day 7 
ns 0.5415 t-test for independent 
samples 
29 TCID50 of 
organs in 
kinetics study 
rVSV-GFP tumor: 
day 1 vs. day 7 
ns 0.5415 t-test for independent 
samples 
32 flowcytometric 
analysis from 
blood in 
kinetics study 
rVSV-NDV 
CD4+: 
day 1 vs.- day 7 
* 0.0112 t-test for independent 
samples 
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32 flowcytometric 
analysis from 
blood in 
kinetics study 
rVSV-NDV 
CD3+: 
day 1 vs.- day7 
ns 0.115 t-test for independent 
samples 
33 FACS analysis 
from tumor  on 
day 7 
CD25+: rVSV-
GFP vs. rVSV-
NDV 
ns 0.2445 t-test for independent 
samples 
Table 6: Statistical Analysis 
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8. Discussion 
Experiments conducted on viral safety of rVSV-NDV compared to rVSV-GFP show an enhanced safety 
profile in immune deficient NOD-SCID mice treated with a dose of 1x106 TCID50. rVSV-NDV treated mice 
survived without any compromise to their general condition, weight development or parameters of renal 
function, which is even more impressive as immune deficient mice were used in this experiment. The 
parameters for liver function appear to be unsteady and fluctuate in a wide range around reference values, 
although several measurements of the serum sample were required until a result within measurable range was 
achieved. The measurement of GPT might be inaccurate because of the high dilution of the serum samples 
required due to limitation in plasma sample volume and the detection limit of the photometer used to evaluate 
the samples. The safety aspect of rVSV-NDV treatment is underlined by the comparatively high viral titers 
of rVSV-GFP found in brain tissue of infected NOD-SCID mice and their illness with neurological 
symptoms on their day of euthanization. Those findings go along with the viral titers found in blood of rVSV-
GFP treated mice on day one and seven after injection. In comparison, there was no titer of rVSV-NDV 
found in brain tissue or blood at the time of euthanasia of NOD-SCID mice. Both treatment groups showed 
low titers of virus in the liver on their day of sacrifice, which might partly be responsible for the parameter 
on liver function to be out of range, although none of the treated mice showed any liver specific symptoms. 
Also, the body weight of rVSV-GFP treated mice decreased along with their neurological illness, which were 
presented in wandering in circles and paralysis, probably due to their inability to reach the food source. 
Another interesting parameter for the study of viral safety would have been the maximum tolerated dose. 
Those experiments were not performed, as it was not possible to achieve titers of rVSV-NDV high enough 
to treat mice with the maximum allowed volume of 100µl per day. It might have been possible to get an 
exception to the maximum applicable volume approved, but due to the production process of the virus, 
where virus-containing supernatant is run over a sucrose gradient and forms a band between the 30% and 
60% sucrose layer, it is to be expected that the virus is solved in approximately 45% Sucrose. As it is 
unpredictable to foresee side effects of the injection of an even increased volume of such a high concentrated 
sucrose-virus mixture, we decided to stay within the recommended volume for intravenous injections.  
Experiments in mice were conducted with 1x107 TCID50 as this is the safe dose for rVSV-GFP in 
immunocompetent mice. Problems in the production of rVSV-NDV might occur due to the ability of the 
virus to form syncytia. This property allows rVSV-NDV to spread inside a given tissue or cell layer, thus 
being protected from the innate immunity, and bypassing the need to produce high yields of progeny virus. 
This could also contribute to the safety aspect of the virus. Furthermore, as an infected cell will fuse to its 
neighbouring cells, a single virion can theoretically infect and kill hundreds of cells, thereby greatly limiting 
the concentration of virus that can be produced from monolayer cell cultures. This problem could be 
addressed by using a non-adhesive cell line for virus production. The lack of cell-to-cell contact and therefore 
the reduced syncytia formation could lead to higher virus yields. 
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Regarding virus shedding, no measurable titer was detected in excretions of AST-LTAg mice in the first three 
days after injection. Concerning the handling of laboratory animals this means that although animals can be 
downgraded to biological security level “S1” after treatment, the body remains “S2” after death by German 
“Act on Genetic Engineering”. It can be concluded that an involuntary contamination of the environment 
by execretions and secretions of treated patients becomes unlikely. Nevertheless, viral shedding needs to be 
verified specifically in the species under investigation and for each virus vector. 
Although we determined that no virus is shed by AST-LTAg mice after 24 hours, it needed to be clarified if 
rVSV-NDV, that might be shed by human patients, or accidentally released into the environment, poses an 
environmental risk for bird populations. The conducted virulence test in 10-day old, embryonated chicken 
eggs led to the conclusion, that rVSV-NDV can be classified as apathogenic. None of the tested viral doses 
killed all the embryos in its group. rVSV-NDV was compared to the parental virus NDV. The virulence test 
for NDV resulted in a minimum lethal dose of 100PFU and a mean death time of 84h, therefore it can be 
classified as mesogenic. 
For the survival study of rVSV-NDV compared to its parental viruses in AST-LTAg mice, the inducible HCC 
model via Ad.Cre injection was used. HCC developed in a gender-specific manner, closely mirroring the 
clinical situation in human patients, whereby males are more susceptible to HCC 7, underlying the translational 
aspect of the model. In our model female mice developed HCC, not only significantly(***) later than male 
mice, but also presented with fewer tumor nodules, which required more time to take over the whole liver. 
Therefore, this survival study was conducted in male mice only, to diminish the impact of different tumor 
growth rates, which would increase the standard deviations within treatment groups and require larger group 
sizes in order to reach statistically significant differences. The survival results of male AST-LTAg mice treated 
with two injections, one when tumors reached inclusion criteria and the second after one week, showed a 
significantly (**) prolonged survival in the rVSV-NDV-treated group compared to PBS-treated mice. The 
mice treated with rVSV-GFP did not show a significant prolongation of survival. It is already well-known 
that systemic delivery is not the optimal delivery route for oncolytic viruses due to immunological barriers 
between the injection site and the tumor107. As the proportions in mice did not allow for hepatic artery 
injection, the delivery route via tail vein injection represents the limitation of this model. Consequently, an 
impaired oncolytic effect in this model was suspected. The fact that the survival of rVSV-NDV-treated mice 
is already prolonged in contrast to the rVSV-GFP-treated mice, could indicate that the mechanisms were 
predominantly immune-mediated rather than a direct oncolytic effect, as we can assume that the tumor 
transduction efficacy was probably minimal. It could indicate an efficient spread inside the tumor tissue, thus 
needing only minimal doses of virus to reach the tumor. An additional kinetics experiment in this model will 
be necessary to get information about the mechanism for the prolonged survival of rVSV-NDV-treated mice.  
The experiments on survival in Buffalo rats did not reveal any significant prolongation of survival in any of 
the virus treated groups compared to the PBS control group. Although the implantation of Morris Hepatoma 
cells is a well-established method in our lab, the tumors implanted in the liver of the Buffalo rats, used for 
this study, led to contact metastases predominantly in the intestines, causing starvation of the implanted rats 
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before they could develop liver-specific symptoms. The survival curve in this case is dependent on the 
localization of the implanted tumor. Tumors implanted far caudal on the left lateral hepatic lobe with only a 
short distance to the intestines tended to metastasize earlier than tumors implanted higher on the liver lobe. 
Because the route of administration of our therapies was semi-selective to the hepatic tumors, via infusion 
into the hepatic artery, it was not expected that the therapy would reach peritoneal metastases. Therefore, we 
speculate that the survival data was greatly skewed by the rapid growth of metastatic lesions, and we believe 
that the data obtained from the respective survival experiment conducted in AST mice and in Buffalo rats, 
treated via intratumoral injection, is more reliable. 
Survival experiments conducted in Buffalo rats with implanted, unifocal HCC lesions and treated via 
inratumoral injection resulted in significantly (*) prolonged survival of rVSV-NDV treated rats compared to 
the PBS control. Again, rVSV-GFP prolonged survival in a not statistically significant scale. That survival 
prolongation could be reached in this model and not via intraarterial injection could be due to the higher 
doses of the oncolytic virus that reach the tumor site when administered intratumorally. After all, AST-mice 
in which significant survival prolongation was achieved, were treated with the same dose (1x107 TCID50) as 
Buffalo-rats. Considering the smaller blood volume of a mouse (mouse approximately 1.7ml, rat 
approximately 22.5ml) the same virus dose was not only exposed to a lower amount of immune-components 
in the mouse model, which probably decreased interference, it also was applied in a higher ratio of OV to 
tumor mass. In addition, the dose of 1x107 TCID50 that was used, as has been proven previously, was the 
maximum tolerated dose for rVSV-GFP in AST-mice. Buffalo rats could, as mentioned above, probably 
tolerate higher virus titers, that were not possible to yield up to know. The fact that the intratumorally treated 
rats showed a prolonged survival compared to the intraarterially injected rats, indicates that a higher virus 
titer administered intraarterially could possibly not only prolong survival of treated rats, but also reach and 
affect metastases. 
Considering statistical significance in the survival studies in combination with the flaws and advantages of 
each model it becomes clear that repeated injections as performed in the mouse model can be an efficient 
approach. Of course, the use of the highest possible safe-dose is beneficial for the outcome and needs to be 
investigated urgently in the rat and mouse model, as the maximum tolerated dose for rVSV-GFP was used 
to perform the experiments. Another factor that could have supported the success in the mouse model is the 
heterogeneity of this highly translational tumor model. It can be assumed that tumor cells of different 
susceptibility to the OV are present in a heterogenic tumor environment, so that the virus can enter the tumor 
tissue via highly susceptible cells and afterwards spread the tumor tissue from the inside. In the homogenic 
tumor model the effectiveness of the treatment depends on the susceptibility of the one cell line used for 
tumor implantation. The contrast between the rat survival studies reveals the necessity to circumvent the 
immune system in the early phase of treatment. This can of course be achieved by intratumoral injection as 
performed in this study or in a hopefully even more effective manner by shielding the virus from recognition 
by the immune system. 
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HCC-bearing Buffalo rats were used for experiments on viral kinetics as well. However, these experiments 
were not completed. Therefore, no statistical analyses should be performed and, although we can speculate 
on trends in the data, no conclusions can be drawn. In this experiment, viral vectors were injected 
intratumorally. Neutralizing antibody assays were performed with plasma of either rNDV-GFP, rVSV-GFP 
or rVSV-NDV treated rats, that were euthanized one or seven days after treatment. The assay showed low 
neutralizing antibody titers for rNDV-GFP as early as on day one after treatment with a titer of 1:100 and a 
similarly low titer on day seven with 1:50. As there was only one rNDV-GFP treated rat, we cannot say 
whether these data are representative. rVSV-GFP treated rats showed an average titer of 1:25 on day seven 
after treatment. This is significantly lower than what was previously reported by the group. Possible reasons 
for the different outcome could be the inter-investigator variation, as well as the different source from which 
the Buffalo rats were obtained. It appears that the rats may have been altered in their immune response, as 
they tended to higher susceptibility to infections after surgery than rats from previous experiments. There 
was no neutralizing antibody titer detected in rVSV-NDV-treated rats at either time-point, but again, group 
size is too small to draw a conclusion. To reveal the point in time when antibodies against rVSV-NDV are 
produced, days 14 and 21 after treatment need to be tested. A potentially delayed production of neutralizing 
antibodies against rVSV-NDV gives opportunity to treat a tumor with a booster injection at day seven after 
treatment, when viral titers decreased in the tumor tissue. This property could also indicate that rVSV-NDV 
could be an optimal vaccine vector, as the immune response could be more directed against the targeted 
tumor antigen, rather than against the virus. Although there were titers of rVSV-GFP and rVSV-NDV on 
day one after treatment, there was no titer detected in rVSV-NDV-treated tumors on the seven-day time-
point. To get more information on the kinetics of viral replication in tumor tissue, additional time-points 
need to be investigated. On day seven after treatment, there were rather high titers of rVSV-GFP in the brains 
of treated rats, although they were injected with a save dose previously determined to be safe in this model 
(1x107 TCID50/rat), and no signs of neurological symptoms could be detected. In contrast, there was no titer 
of rVSV-NDV or rNDV-GFP in the brains of treated rats. This also stresses the importance of the 
development of a viral vector that is non-replicative in neurons. Although there were higher titers of rVSV-
GFP found in tumor tissue, the titers of rVSV-GFP in healthy liver tissue on the seven-day time-point and 
the titer found in brain tissue make rVSV-GFP appear less tumor-specific than rVSV-NDV. Furthermore, it 
remains to be seen whether the increased intratumoral titer translates to enhanced efficacy compared to 
rVSV-NDV. 
The co-culture experiment of McA-RH7777 cells with PBMCs derived from blood of rVSV-NDV, rVSV-
GFP or PBS treated rats turned out to be inaccurate and not suitable to detect delicate variances as would be 
necessary in the test results. The amount of cell-counting steps involved in this experiment, might have led 
to a subsequent aberration, explaining variation in detected cell viability within experimental groups.  A better 
way to test antitumor immune responses could be an ELISA assay from serum samples for T cells directed 
against TAEs. To better determine any effect of tumor-specific T cells in response to the respective therapies, 
later time-points will need to be investigated. 
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T cells were also used for flow cytometric analysis. The results indicate an increased T cell activation in rVSV-
NDV treated rats in comparison to rVSV-GFP treated rats on day one after treatment, although this data is 
only based on one or two treated rats per group. These findings go along with other studies that revealed a 
strong immunogenic effect of the F and HN protein of NDV64, which in VSV-NDV seems to activate T 
cells as well. However, it is unlikely that this effect would be evident already after only 24hours post treatment. 
Seven days after intra-tumoral injection, there are higher percentages of living T cells to be found in blood 
samples. The increased stimulation of T cells on day seven after treatment, even in the PBS treated rat, 
indicates that the surgery performed to inject substances into the tumor might be partly responsible for the 
immune stimulation. To overcome the impact of immune stimulation through surgical intervention, ongoing 
experiments could be performed via ultrasound guided intra-tumoral injection through the skin. Findings 
from flow cytometric analysis of tumor invading T cells on day seven after treatment resulted in enhanced 
CD8+ T cell activation in the rNDV-GFP group. 
Ongoing experiments on the effectiveness of rVSV-NDV will be performed by the addition of days 3, 14 
and 21 after treatment to the experiments on viral kinetics and addition of AST-LTAg mice to the survival 
experiment. Histological and immunohistochemical data from tumor tissue will also provide important 
information regarding necrosis, apoptosis, and inflammatory cell infiltration. Moreover, insight into 
replication, kinetics and biodistribution of rVSV-NDV can be gained by PET/CT- or PET/MR-imaging of 
animals through the use of reporter genes, such as the herpes simplex thymidine kinase gene, into the rVSV-
NDV vector. Other plans to enhance the efficacy of the hybrid-virus include the introduction of molecules 
to modulate immune checkpoints, such a soluble PD1 into rVSV-NDV vector, to circumvent T cell 
inactivation by tumoral PD-L1. Furthermore, a combination with adoptive T cell therapy will be investigated. 
In conclusion, rVSV-NDV proved to be a safe oncolytic agent in the investigated doses. There was no 
neurotoxicity or other organ failure detectable in treated immunosuppressive mice. In addition, concerns in 
terms of viral shedding are diminished by the fact that there is no virus measurable in excretions of treated 
AST-LTAg mice. The pathogenicity of rVSV-NDV in avian species was tested by inoculation of embryonated 
chicken eggs to confirm its degree of pathogenicity. rVSV-NDV is proven to be apathogenic. 
In terms of rVSV-NDV’s effectiveness, it showed tendencies of promising survival prolongation in AST-
LTAg mice and Buffalo rats, treated via intratumoral injection, and a stronger antitumor immune stimulation 
than its viral backbone VSV. The fact that rVSV-NDV-specific antibodies are not produced within the first 
seven days after application gives the opportunity to use a booster application one week after treatment start 
to enhance the oncolytic effects of rVSV-NDV. 
rVSV-NDV can be a safer replacement of the already effective parental viruses. Ongoing experiments with 
the hybrid virus will be conducted to prove its enhanced effectiveness and to establish a safe delivery route 
that shields the virus from early, unspecific immune responses. The viral vector VSV-GP95 is in many aspects 
comparable to our developed VSV-pseudotype. A direct comparison of the key aspects important for 
68 
preclinical investigations will pronounce weaknesses and strengths of both vector types and set them apart 
as both valuable contributions to the OV- therapy landscape. 
Both recombinant virus vectors follow the strategy to replace the tropism-mediating glycoproteins on the 
VSV envelope with glycoproteins of a different oncolytic agent to circumvent VSVs efficient infection of 
neurons108 and also to gain new functions such as syncytia development4 and advantages like loss of 
neutralizing antibody development by a well-matched pairing. To prove the success in achieving a safer 
oncolytic agent, vector administration in rodents was tested and led to the conclusion that both viruses can 
be applied safely in these model organisms. Both vectors have been tested in immunodeficient mice to further 
underline the safety aspect. As it was possible to achieve higher virus titers for the rVSV-GP pseudotype, it 
was injected in a dose of 108 PFU, whereas rVSV-NDV was injected in a dose of 106 PFU. Nevertheless, 
application of both vectors did aside from a minor loss in body weight at the beginning not lead to any health 
concerns in the immunodeficient mice. All mice in those studies have been euthanized at the end of the 
observation period without any signs of illness. For rVSV-GP systemic safety was tested by injection of 
109PFU in immunodeficient CD-1 mice. There were no death events in the rVSV-GP treatment group to be 
observed. Although rVSV-NDV has not been tested to specifically prove systemic safety, it was used for 
treatment of immune competent AST mice that had to be euthanized in the end, but due to tumor burden 
and not as a result of toxic events induced by the virus. 
VSV-NDV and VSV-GP were tested to rule out off-target toxicity. Here the results do as well show a 
similarity. There were no elevated titers of creatinine to be measured, neither in the rVSV-GP95 nor in the 
rVSV-NDV treated mice. Serum level for GPT on the other hand were slightly increased in the rVSV-GP 
treated animals and off-range for the rVSV-NDV treated animals, although measurements in the rVSV-NDV 
treated group had to be repeated several to times to achieve a result within the detection range of the 
instrument. Despite these findings that indicate a marginal damage of liver cells RT-PCR of rVSV-GP treated 
animals to determinate viral existence in non-tumoral liver cells revealed a rapid clearance from the tissue 
after injection and histologic examination of non-tumoral liver cells in rVSV-NDV treated animals did not 
display cell damage. 
The most interesting aspect of course is the recombinants efficacy in treatment of tumor cells and spheroids 
in vitro and massive tumors in vivo by different application routes (intratumoral or systemic). 
Both vectors have been tested in a variety of tumor cells and rodent tumor models. As susceptibility of the 
tumor cells is highly dependent on their impaired IFN response, an IFN assay can reveal first clues about the 
likeliness of a successful infection of the tumor in question. Even cell lines with an intact innate immune 
response can be made susceptible to the OV treatment by a pre-treatment with ruxolitinib. This inhibitor of 
Janus kinase (JAK)1 and 2 can successfully overcome the cells IFN protection as shown in in vitro assays as 
well as in vivo studies on treatment efficacy of VSV-GP in tumors with reduced susceptibility29. Nevertheless, 
a co-application of both, ruxolitinib and the oncolytic vector should be considered carefully and the effects 
on off-target toxicity should be re-evaluated. 
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The viruses under investigation were tested for susceptibility and efficacy in different types of cancer, the 
following section will give a short overview over their outstanding features. More details of the tested model 
systems (cell lines implanted, model organism, implantation site, administration route etc.) are attached in a 
table. It has to be mentioned that a direct comparison of treatment doses between the viruses VSV-GP and 
VSV-NDV is complicated, because VSV-GP has generally been measured in PFU, whereas VSV-NDV (as a 
syncytia forming virus) cannot be measured in the same way and is quantified in TCID50. 
In general, VSV-NDV has been tested for the use in HCC. Here we have data showing successful infection 
of human HCC cell lines derived from patients and we are able to show not only successful infection, but 
also a delayed tumor growths in immune competent rodent HCC models after intratumoral injection and in 
the mouse model as well after systemic injection of the OV as described in [6. Results]. Other tests that have 
been conducted on VSV-NDV revealed a good susceptibility to a lung carcinoma cell line in an in vitro 
Interferon response assay [3.2 Preliminary data]. The virus VSV-GP has been tested in several cancer models 
with different outcome. The infection and treatment success seems to be pronounced especially in models 
of glioma in vitro and in vivo. Susceptibility was variable in different models of ovarian cancer, malignant 
melanoma (human, mouse and dog cell lines) and prostate cancer. All models revealed cell types with different 
infection rates. It was possible to circumvent reduced susceptibility with great treatment success via a 
combination treatment scheme of VSV-GP and ruxolitinib.  
As mentioned above VSV-GP proved as a competent oncolytic vector in the treatment of malignant glioma. 
Although it showed lower infection and replication rates compared to wild type VSV, infection of monolayers 
or spheroids of malignant glioma in vitro led to rapid replication and complete cell cytotoxicity within a few 
days. Tests concerning the oncolytic abilities of VSV-GP were conducted in immunodeficient mice in a 
heterotopic tumor model and an orthotopic tumor model as well as in immune competent mice. Intratumoral 
injection of VSV-GP in subcutaneously implanted tumors in SCID mice cured all of the treated mice. SCID 
mice implanted with intracerebral tumors showed prolonged survival after the intratumoral treatment with 
VSV-GP (71 days post transplantation or event-free long time survival over more than 125 days) when 
compared to the PBS control group (median survival 33 days post transplantation). Immune competent mice 
with intracerebral tumors treated via i.t. injection also enhanced survival after transplantation. Median survival 
in the treatment group was 81 days post transplantation (treatment 10 days after transplantation) compared 
to the PBS control with 29 days post transplantation. Additionally five out of ten animals showed event free 
long-term survival95. VSV-GP has been tested as well in ovarian cancer. In vitro susceptibility of the tested 
cells showed different outcomes among the tested cells. As it turned out human ovarian surface epithelial 
cells (HOSE) do only show limited susceptibility and do not lyse the cells even at an MOI of 1. Nevertheless, 
HOSE cells were implanted subcutaneously in NOD-SCID mice and different treatment schemes from OV 
monotherapy to a combination therapy of OV and ruxolitinib have been tested. The VSV-GP monotherapy 
treatment scheme led to seven cured animals out of ten, but tumors recurred approximately between 25 and 
50 days after treatment start. The combinational therapy with VSV-GP and ruxolitinib led to a reduced 
recurrence of cured tumors in only three out of nine cured mice. Via i.p. injection orthotopically implanted 
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ovarian cancer cells in immunodeficient mice could partly be cured with VSV-GP treatment. Tumor 
remission was observed in three out of eight mice. Again the combination treatment scheme of VSV-GP and 
ruxolitinib increased the treatment success and led to tumor remission in seven out of eight mice, which were 
considered cured after a 100 day observation period29. Tests on the therapeutic efficacy for the treatment of 
malignant melanoma again revealed different infection rates when used in vitro in human, murine and dog cell 
lines. Five out of ten cell lines derived from primary human melanoma were susceptible for infection with 
VSV-GP. The one tested mouse and dog cell line showed good susceptibility. Heterotopic implantation  of 
the mouse melanoma cell line in immune competent mice and treatment via intratumoral injection of VSV-
GP showed dose-dependent effects. Mice in the PBS control group had a median survival of 18 days, whereas 
treatment with VSV-GP in the highest administered dose (2.36x107 PFU ) led to a median survival of 25.5 
days with complete remission in three out of twelve treated mice. In this tumor model a treatment via the 
systemic administration route (2.36x107 PFU ) was applied as well and led to a median survival of 22 days 
(maximum 32 days) in the virus treated group compared to the PBS control with 17.5. days median survival109. 
VSV-GP has also been tested in prostate cancer. In contrast to the melanoma and ovarian cancer cell lines 
were reduced susceptibility was observed, all cultures of prostate cancer seemed to be sensitive for infection 
in vitro, yet heterogeneous killing rates ranging between 60% and 20% have been observed. The treatment 
efficacy was investigated in vivo by intratumoral or systemic injection into immunodeficient mice with 
heterotopic tumors and by systemic injection into immune competent mice. Tumors were generated by 
implantation of either of two susceptible cell lines with reduced IFN competence. A treatment scheme of 2 
intratumoral injections of 107 PFU in subcutaneous tumors led to full tumor remission without relapse in a 
100 day observation period. Systemic treatment of heterotopic tumors had dose dependent outcome with six 
out of six animals cured without relapse in a 86 day observation period, when treated with the highest dose 
(108 PFU). Systemic treatment of heterotopic tumors in immune competent mice led to growth delay and 
significant prolongation of median survival110. 
Comparing the treatment success of VSV-NDV and VSV-GP, it is noteworthy that none of the animals 
under investigation in survival studies had to be euthanized due to neurological illness or other sickness 
caused by organ failure. VSV-GP has been tested in a broad variety of different tumor models, administration 
schemes and combination treatment with the ruxolitinib. It became apparent that VSV-GP does not 
efficiently kill all the tumor cell lines under investigation, but was often successful when used in combination 
treatment with ruxolitinib to circumvent IFN responses. When compared to the oncolytic activity of VSV-
NDV it becomes apparent that both viruses seem to improve upon sequential application. The most 
successful application route still seems to be the intratumoral injection for both viruses tested, although 
treatment success for VSV-GP in the prostate cancer and melanoma models  and for VSV-NDV in the 
treatment of HCC in the mouse model showed promising results via systemic application as well. 
Intratumoral injection of VSV-GP in different tumor models in immunodeficient mice often led to complete 
remission, which is a great treatment success, but still the more artificial system than immune competent 
rodents. For models tested with VSV-GP or VSV-NDV under the same attributions (immune competent 
host, orthotopic cancer model, virus monotherapy, administration by intratumoral injection) which applies 
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for treatment of malignant glioma treated with VSV-GP and HCC treated with VSV-NDV the outcome is 
comparably well in both virus vector systems. All things considered, treatment with the oncolytic vector VSV-
GP was able to cure immunodeficient mice with different tumor models, both viral vectors led to prolonged 
survival in immune competent mice (and rats) after intratumoral injection and partly after systemic injection. 
Another important aspect as already described before is the circumvention of humoral immune responses as 
this might give the viral vector the advantage of time to lyse the tumor cells before being cleared. For VSV-
GP, treatment does not induce neutralizing antibodies against VSV or VSV-GP, at least within a time frame 
of 26 days. This gives the opportunity for booster injections of the vector to induce a second stage of cell 
lysis and enhance inflammation within the tumor bed by CTLs32. For VSV-NDV, no production of 
neutralizing antibodies could be observed within 7 days after treatment. This period was successfully used 
for a booster application of the oncolytic vector and we were able to show an improvement of the survival 
data in the mouse survival studies upon repeated administration. 
Another approach that will be tested with VSV-NDV in future studies is the effect on using the virus as a 
vaccine against tumoral antigens. VSV-GP has been tested in that matter by introducing an OVA antigen 
into the vector and treatment of naïve C57BL/6 mice with the serum of VSV-GP-OVA or VSV-OVA treated 
mice. The study resulted in T cell responses after challenge with VSV-GP-OVA directed against OVA in the 
VSV-GP-OVA group, but not in the VSV-OVA group. To further prove the effectiveness of the vaccination 
scheme VSV-GP-OVA pre-immunized mice were challenged with a Listeria monocytogenes (Lm) expressing 
OVA. After scarification of the mice the bacterial load measured in the spleen was below detection limit, 
whereas in the control group high levels of Lm-OVA could be found32 .  
The comparison of both vectors underlines what is already well known, that oncolytic virus face similar 
obstacles especially concerning the accessibility of the tumor and rapid clearing by immune responses. On 
the other hand, a broad landscape of OV vectors with different profiles in susceptibility and immunologic 
impact can contribute to an individualized treatment scheme for different cancerous diseases. 
The use of the oncolytic virus vector investigated in our studies could not only provide a benefit for survival 
of HCC patients on the transplant list until a suitable transplant is available, with some additional effort in 
terms of shielding the virus or improved delivery routes it could even be curative and not only for the solid 
primary tumor lesion but as well for metastases in all kinds of organs. Until now the most successfully treated 
tumors have been melanomas, as they are mostly available for intratumoral treatment because of their 
comparingly superficial location.  
A barrier in veterinary medicine poses the treatment of equines, cattle, pig and poultry. The virus’s origin 
from animal viruses affects its usability for animal patients.  It can be assumed that the use in the parental 
virus’s natural hosts cannot be considered safe. In addition, the effectiveness of the treatment will probably 
suffer from preexisting immunity, due to a much higher epidemic infestation than can be assumed in humans. 
Nevertheless small animal patients could profit from the development of this treatment approach. 
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For future patients of carcinogenic diseases of all kinds it will be vital for the treatment success to have a 
broad variety of treatment strategies to choose from. Not only to address the individuality of each tumor, but 
as well to attack cancer with ever changing approaches and eventually exhaust its ability to circumvent 
destruction. Oncolytic viro-immunotherapy in general and specifically rVSV-NDV as oncolytic agent could 
provide an alternative platform to target tumor cells, break immune tolerance towards tumor antigens, 
stimulate the immune response and even vaccinate against tumor antigens to protect from recurring tumor 
growth. 
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9. Summary 
This study investigated the recombinant virus, rVSV-NDV, for its safety and effectiveness in vivo. To gain 
insight into the safety of the application of the hybrid-virus, experiments on toxicity in liver, kidney and brain 
of treated NOD-SCID mice were performed in comparison to NOD-SCID mice treated with the parental 
virus VSV. The results revealed that a safe use of the oncolytic viral vector is possible and no harm to basic 
organ function is expected. To rule out an environmental risk to exposed birds a study on the pathogenicity 
of rVSV-NDV in embryonated chicken eggs was performed. Based on this experiment, the hybrid-virus, 
rVSV-NDV, can be classified as apathogenic. Conducted Survival experiments in AST mice, treated via tail 
vein injection, and Buffalo rats, treated via intratumoral injection, resulted in enhanced prolongation of 
survival in the rVSV-NDV-treated group compared to the rVSV-GFP treated group and significantly 
enhanced prolongation compared to the PBS control. A survival experiment, conducted in Buffalo rats, 
treated via intraarterial injection, was performed in order to safe the virus from unspecific immune responses 
by a more translational delivery route via the hepatic artery. The results from the mouse survival experiment 
were not reproducible in this rat survival experiment. Although the tumor model, used in this experiment is 
well-established in our group, there were peritoneal metastases in tumor implanted rats that were interfering 
with the survival results. The contrast to the results of the intratumorally injected rats suggests that a smaller 
virus dose reached the tumor bed compared to the direct injection, which stresses the need to investigate 
improved virus production protocols that lead to higher virus yield and allow to treat using the maximum 
tolerated dose. Experiments on viral kinetics were conducted in groups too small to draw a real conclusion, 
but give a hint referring to the virus’s replication in different tissues and development of neutralizing 
antibodies. The results indicated a potentially delayed development of neutralizing antibodies, which gives 
the opportunity for a booster injection of the oncolytic virus. In addition, the hybrid-virus does not seem to 
replicate in the brain of treated NOD-SCID mice or rats. In tumor tissue it replicates to titers lower than the 
titers of the parental virus VSV. 
To get rVSV-NDV into clinical translation the most important step will be to further improve virus 
production and examine the maximum tolerated dose as a safe and effective treatment dose. Additionally a 
multi-injection regimen as already used in OV-therapy in the clinic should be applied. 
  
74 
  
  75 
10. Zusammenfassung 
In dieser Arbeit wurde das rekombinante Virus VSV-NDV auf seine Sicherheit und Effektivität in vivo 
untersucht. Um die Sicherheit der Anwendung des neuen Hybridvirus zu untersuchen, wurden Experimente 
bezüglich der Toxizität in Leber, Niere und Gehirn in NOD-SCID Mäusen durchgeführt. Die Ergebnisse 
zeigen, dass eine sichere Anwendung von rVSV-NDV möglich ist und nicht zu einer Einschränkung der 
Funktion grundlegender Organe führt. Des Weiteren wurde die Virulenz des Virus in Vögeln an 
embryonierten Hühnereiern untersucht, um ein eventuell vorhandenes Risiko für exponierte Tiere 
abschätzen zu können. Die Ergebnisse der Untersuchung lassen eine Einstufung von rVSV-NDV als in 
Vögeln apathogenes Virus zu. Durchgeführte Überlebensexperimente bezüglich des Therapieeffekts in AST-
Mäusen, behandelt über Injektion des OV in die Schwanzvene, und in Buffalo-Ratten, behandelt über 
intratumorale Injektion des OV, resultierten in verlängerter Überlebenszeit rVSV-NDV behandelter Mäuse 
im Vergleich zu rVSV-GFP behandelter Mäuse und signifikant verlängerter Überlebenszeit gegenüber der 
PBS-Kontrollgruppe. Es wurde ebenfalls ein Überlebensexperiment in Buffalo-Ratten durchgeführt, bei dem 
das Virus über eine Injektion in die tumorversorgende A. hepatica propria appliziert wurde, um das Virus auf 
seinem Weg ins Tumorbett vor unspezifischen Immunreaktionen zu schützen. In diesem Experiment 
konnten die Ergebnisse aus dem Experiment an AST-Mäusen nicht reproduziert werden. Obwohl das in 
diesem Versuch angewendete Tumormodell in unserer Arbeitsgruppe bereits lange etabliert ist, neigten die 
tumorimplantierten Tiere zur Ausbildung von peritonealen Metastasen, die maßgeblich die Überlebenszeit 
der Tiere beeinflussten. Die stark unterschiedlichen Ergebnisse der Überlebensstudien in Ratten lassen den 
Rückschluss zu, dass bei der intraarteriellen Injektion des OV eine wesentlich kleinere Virusmenge das 
Tumorbett erreicht, im Vergleich zur direkten Applikation über die intratumorale Injektion. Dieser Schluss 
unterstreicht die Notwendigkeit ein effizienteres Protokoll zur Virusproduktion zu untersuchen, das zu 
höheren Virustitern führt und die Applikation der maximal tolerierten Dosis zur Behandlung erlaubt. 
Experimente zur Untersuchung der Viruskinetik wurden in sehr kleinen Gruppen durchgeführt, die eventuell 
einen Hinweis geben auf die Replikation von rVSV-NDV in verschiedenen Geweben und die Bildung 
neutralisierender Antikörper. Die Ergebnisse weisen auf eine, im Vergleich zu den Kontrollviren VSV und 
NDV, verzögerte Bildung neutralisierender Antikörper hin. Zu den untersuchten Zeitpunkten an Tag eins 
und sieben nach Therapiebeginn liegen keine Hinweise auf neutralisierende Antikörper gegen rVSV-NDV 
vor. Dadurch könnte die Möglichkeit einer Auffrischungsinjektion an Tag sieben nach Therapiestart 
bestehen. Weitere Untersuchungen zur Replikation des Hybridvirus in Gehirn, Leber und Tumorgewebe 
weisen darauf hin, dass rVSV-ND nicht im Gehirn behandelter NOD-SCID-Mäuse oder Ratten repliziert. 
Im Tumorgewebe behandelter Ratten wurden niedrigere Virustiter für rVSV-NDV nachgewiesen als für den 
Kontrollvirus VSV. 
Die wichtigsten Schritte um rVSV-NDV auf einen Start im klinischen Alltag vorzubereiten, werden die 
Optimierung der Produktion und die Untersuchung der maximal tolerierten Dosis als sichere und effektive 
Behandlungsdosis sein. Außerdem sollte ein Behandlungsregime mit wiederholter OV-Applikation, wie 
bereits üblich in der Krebstherapie mit onkolytischen Viren, angewendet werden.  
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14. Abbreviations 
 
Ad.Cre   Cre-recombinase expressing Adenovirus 
AST-LTAg  Albumin-floxstop-large T-antigen 
APC    Antigen presenting cell 
BUN   Blood urea nitrogen 
Caspase  Cysteine-Aspartatic-Proteases 
CD   Cluster of differentiation 
CNS   Central nervous system 
CPE   Cytopathic effect 
CREA   Creatinine 
CSF   colony-stimulating factor 
DC   Dendritic cell 
DNA   Deoxyribonucleic acid 
EDTA   Ethylenediaminetetraacetic acid 
EMA   European Medicines Agency 
ER   Endoplasmic reticulum 
ERK   Extracellular signal-regulated kinases 
FACS   Fluorescence-activated cell sorting 
Fas   First apoptosis signal receptor 
FDA   U.S. Food and Drug Administration 
F  Protein  Fusion protein 
GFP   Green fluorescent protein 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
G Protein  Glycoprotein 
GPT   Glutamate-Pyruvate-Transalaminase 
HBV   Hepatitis B virus 
HCC   Hepatocellular carcinoma 
HCV   Hepatitis C virus 
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HepG2   Human HCC cell line 
hIFNβ   Human interferon β 
HN Protein  Hemagglutinin-Neuraminidase 
Huh7    Human HCC cell line 
ICP   Infected cell protein 
IFN   Interferon 
IL   Interleukin 
ISG   Interferon stimulated genes 
IVC   Individually ventilated cage 
LDH   Lactate dehydrogenase  
LDH(R)   High density lipoprotein (Receptor) 
LDL(R)   Low density lipoprotein (Receptor) 
L Protein  Large protein 
MHC   Major histocompatibility complex 
MOI   Multiplicity of infection 
M Protein  Matrix protein 
mRNA   Messenger RNA 
MTS   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NDV   Newcastle Disease Virus 
NK   Natural killer cell 
NOD-SCID  Non Obese Diabetic-Severe Combined Immunodeficiency 
N protein  Nucleocapsid protein 
NS1   NS1 influenza protein, non-structural protein 
OIE   World Organization for Animal Health 
OV   Oncolytic virus 
P53   Tumor suppressor gene 
PAMP   Pathogen associated molecular patterns 
PBMC   Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
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PD-1   Programmed cell death protein 
PD-L1   Programmed cell death 1 ligand 1 
PFU   Plaque forming unit 
P Protein  Phosphoprotein 
PRR   Pattern recognition receptor 
Raf 1   Proto-oncogene 
Ran   Ras-related nuclear protein 
Ras   Proto-oncogene 
Rcf   Relative centrifugal force 
RdRp   RNA-dependent RNA polymerase 
RIG-I   retinoic acid inducible gene I 
RNA   Ribonucleic acid 
STAT   Signal transducer and activator of transcription 
TAA   Tumor associated antigen 
TACE   Transarterial chemoembolization 
TCID50   50% Tissue culture infective dose  
TCR   T-cell receptor 
TGF   transforming growth factor 
TK   Thymidine kinase 
TLR   Toll-like receptor 
TNF   Tumor necrosis factor 
TRAIL   TNF-related apoptosis-inducing ligand 
T-VEC   Talimogene laherparepvec 
USDA   United States Department of Agriculture 
VSV   Vesicular stomatitis virus 
VSV-IN   VSV, serotype Indiana 
VSV-NJ   VSV, serotype New Jersey 
VSV-NDV Pseudotyped vesicular stomatitis virus with glycoproteins of Newcastle 
Disease Virus 
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15. Attachments 
Supplementary Table 1: Experimental conditions and results in the development of rVSV-(LCMV)GP 
Cancer 
type 
Model specifications Response to Treatment  
Malignant 
glioma 
 
In vitro Good performance in monolayers and spheroids 
In vivo Hetero
-topic 
Immuno-
deficient 
Mouse model: NOD.CB17-Prkdcscid/J 
Tumor model: G62 human glioblastoma 
Treatment dose: 2x105 PFU  
 
Heterotopic (s.c.) tumors from G62 cells treated by i.t. 
injection were cured 
Ortho-
topic 
Immuno-
deficient 
Mouse model: NOD.CB17-Prkdcscid/J 
Tumor model: U87-RFP human glioblastoma 
Treatment dose: 1x108 PFU  
 
Orthotpic (intracerebral) tumors from U87 cells treated by 
i.v. injection led to median survival of either 71 days post 
transplantation or event free survival of more than 125 days 
compared to 33 days in PBS control group 
Immune 
competent 
Mouse model: C57BL/6NCrl 
Tumor model: CT2A glioma (CT26-lacZ) 
Treatment dose: 2.5x107 PFU  
 
Treatment with and rVSV-GP administered intracranially 
led to median survival 81days post transplantation (dpt) vs. 
PBS 29 dpt. 5 of 10 animals showed event-free long-term 
survival. Test of effectiveness for brain metastases with 
colon carcinoma injected intracranially led to  9 animals 
durable cured without off-target effects out of 11. 
Melanoma In vitro  6 human melanoma cell lines showed good 
susceptibility for VSV. VSV-GP had different 
susceptibility between the cell lines. 
 1 mouse melanoma cell line (B16-OVA)  good 
susceptibility of both viruses. 
 1 dog melanoma cell line (UCDK9-M1)  high 
susceptibility of both viruses (VSV, VSV-GP). 
Efficient killing of melanoma cell lines in mouse and dog 
cell line and 4 out of 6 human cell lines. 
Susceptibility and killing efficacy in primary human 
melanoma derived from 10 patients: 
Successful infection with VSV-GP-GFP in 5 out of 10 cell 
lines 
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In vivo immunodeficient  Mouse model: NOD.CB17-Prkdcscid/J 
Tumor model: A375 (xenograft) 
Treatment dose: 107PFU 
 
Treatment via i.t. injection led to median survival of 45 days 
(PBS 22 days). 
immune competent  Mouse model: C57BL/6J 
Tumor model: murine B16-OVA cells 
Treatment doses: 2.36x104PFU, 4.72x105, 2.36x107 
 
Treatment via i.t. injection was most efficient with the 
highest dose 2.36x107 tested. Median survival was prolonged 
to 25.5. days compared to PBS control (18days). Complete 
remission was observed in 3 out of 12 animals. 
Treatment via i.v. injection was tested with 2.36x107PFU. 
Median survival was prolonged to 22 days (longest survived 
32) in contrast to PBS 17.5 days. 
Ovarian 
cancer 
In vitro  Both viruses (VSV*G-G and VSV*G-GP) 
infected all cell lines, most cell lines are more 
susceptible to VSV*G-G 
 Reduced susceptibility of both viruses in benign 
cell line HOSE 
 Experiments on replication show a slightly 
attenuated behavior of the chimeric VSV*G-GP 
(titer one log lower than wt-VSV at 24h post 
infection) compared to wt-VSV (replication peak 
24h after infection) 
 MOI of 0.1 leads to complete loss of cell viability 
72h after infection 
 HOSE cell line could not be lysed by either virus at 
MOI 1 
 Addition of ruxolitinib enhanced virus titers 
significantly  comparable levels to control cells 
In vivo Heterotopic 
immunodeficient 
Mouse model: NOD.CB17-Prkdcscid/J 
Tumor model: A2780 human ovarian caner 
Treatment  dose: 5x106 PFU 7 day interval 
 
Combination therapy of s.c. tumors treated with VSV-GP 
and ruxolitinib or monotherapy with VSVS-GP significantly 
reduced the tumor size. Combination therapy led to smaller 
tumors and reduced recurrency (3/9 mice) in contrast to 
monotherapy (7/10). 
Orthotopic 
immunodeficient 
 
Mouse model: athymic nude-Foxn1nu 
Tumor model: A2780 human ovarian cancer expressing 
luciferase 
Treatment  dose: 107PFU 
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Tumors were implanted by i.p. injection of A2780 cells. 
Four treatment groups have been tested (non-treated, 
ruxolitinib, virus, virus + ruxolitinib). Treatment was 
performed with ruxolitinib and virus via i.p. injection 
(107PFU at days 0, 3 and 7). The group treated with the 
virus only showed tumor remission in 6 out of 8 animals. 
The group treated with virus + ruxolitinib led to tumor 
remission in 1 out of 8 animals. 
 Doses of 108 or 109 did not lead to toxicity in ruxolitinib 
treated animals (toxicity is not enhanced). 
 Prostate 
cancer 
In vitro  6 human and 1 murine cell line (PCa)  VSV-GP 
efficiently killed 4 cell lines 
 2 cell lines in bone marrow (mimic metastases)  
effectively killed by VSV-GP 
 Inefficient cell killing in VCaP and LNCaP (maybe 
due to lack of a-destroglycan expression on the 
surface)  increasing virus dose 100fold induced 
killing rates comparable to sensitive cell lines 
 Primary cultures from patient samples have been 
tested for sensitivity and killing rates  all cultures 
were sensitive, yet killing rates heterogeneous 
ranging between 60%-20% survival 
 PCa cell lines have heterogeneous capability of 
producing an IFN-response 
In vivo Immunodeficient 
 
Mouse model: Balb/c Rag2-/-c-/- 
Tumor model: Du145 cells, 22Rv1 cells  
Treatment  dose: 107 PFU VSV-GP-Luc or VSV-GP-GFP 
 
Treatment via i.t. injection: 
Intratumoral injection in xenograft models (s.c. Du145) 
tumors were treated with 2 injections of 107 PFU VSV-GP 
via  i.t. injection. The treatment induced full tumor 
remission and no relapse during a 100-day observation 
period. 
22Rv1 tumors implanted s.c. were treated with a single dose 
2.3x108PFU VSV-GP. 6 out of 7 mice responded well to the 
treatment (5/7 tumor remission, 1/7 stable disease). Mice 
treated with a single dose of 3.3x105 led to tumor growth 
delay in 3 out of 7 mice , stable disease in 1 out of 7 mice. 2 
out of 7 mice showed tumor remission. 
VSV-GP-Luc was detectable in tumors as early as day 1-9 
after treatment. 
 
Treatment via i.v. injection: 
Subcutaneously implanted 22Rv1 tumors treated with 108 
PFU showed complete response in 6 out of 6 animals. 
Those survived the 86 days observation period. 
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Immune competent Mouse model: C57BL/6JRj 
Tumor model: TRAM-C1 cells 
Treatment  dose: 108 PFU 
 
3 doses of VSV-GP administered i.t. led to tumor growth 
delay and significant increase of median survival (presence 
of VSV-GP-Luc in the syngeneic model was shorter than in 
xenograft model). 
 
